Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,7.199999809265137,7.389999866485596,6.800000190734863,7.369999885559082,20686,0.0,0.0,,,,,,,,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-06-28,7.369999885559082,7.489999771118164,7.369999885559082,7.389999866485596,6824,0.0,0.0,,,,,,,100.0,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-06-29,7.480000019073486,7.480000019073486,6.949999809265137,7.139999866485596,3818,0.0,0.0,,,,,,,6.914887478471002,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-06-30,7.159999847412109,7.230000019073486,6.940000057220459,6.949999809265137,17010,0.0,0.0,,,,,,,3.9247520470539143,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-01,6.960000038146973,7.0,6.900000095367432,6.900000095367432,34175,0.0,0.0,,,,,,,3.4962906132660834,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-04,6.96999979019165,7.380000114440918,6.619999885559082,7.369999885559082,37129,0.0,0.0,,,,,,,54.157892375207105,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-05,6.989999771118164,7.46999979019165,6.599999904632568,6.889999866485596,14176,0.0,0.0,,,,,,,34.33403891435694,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-06,6.889999866485596,6.889999866485596,6.400000095367432,6.550000190734863,47879,0.0,0.0,,,,,,,26.839800046062848,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-07,6.550000190734863,6.869999885559082,6.489999771118164,6.869999885559082,26574,0.0,0.0,,,,,,,40.09337989098387,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-08,6.869999885559082,6.869999885559082,6.46999979019165,6.800000190734863,7869,0.0,0.0,7.022999954223633,,,-3.175277871882338,,,38.45236458320727,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-11,6.800000190734863,6.980000019073486,6.690000057220459,6.75,13076,0.0,0.0,6.960999965667725,,,-3.031173203683312,,,37.27865566750005,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-12,6.75,6.75,6.5,6.730000019073486,4521,0.0,0.0,6.894999980926514,,,-2.3930378870117925,,,36.79485435281436,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-13,6.889999866485596,6.889999866485596,6.369999885559082,6.480000019073486,25430,0.0,0.0,6.828999996185303,,,-5.110557582468425,,,31.322670351390727,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-14,6.119999885559082,6.599999904632568,6.119999885559082,6.460000038146973,29914,0.0,0.0,6.780000019073486,,,-4.719763717201918,,,30.92641292884514,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-15,6.0,6.699999809265137,5.900000095367432,6.699999809265137,45540,0.0,0.0,6.759999990463257,,,-0.8875766461947636,,,40.632291354845826,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-18,6.699999809265137,6.699999809265137,6.5,6.650000095367432,3924,0.0,0.0,6.688000011444092,,,-0.5681805623749533,,,39.39048039188759,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-19,7.0,7.0,6.71999979019165,6.739999771118164,6681,0.0,0.0,6.673000001907349,,,1.0040426973125203,,,42.78038307299557,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-20,6.659999847412109,6.699999809265137,6.650000095367432,6.650000095367432,13795,0.0,0.0,6.682999992370606,,,-0.4937886733629698,,,40.350000637044126,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-21,6.699999809265137,6.699999809265137,5.75,6.550000190734863,15145,0.0,0.0,6.651000022888184,,,-1.5185661074387027,,,37.78165066749712,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-22,6.5,6.599999904632568,6.300000190734863,6.599999904632568,25518,0.0,0.0,6.630999994277954,,,-0.4675024833680685,,,39.84344907743658,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-25,6.599999904632568,6.599999904632568,6.400000095367432,6.579999923706055,9369,0.0,0.0,6.61399998664856,,,-0.5140620352455386,,,39.28269080437863,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-26,6.579999923706055,6.579999923706055,6.449999809265137,6.5,5724,0.0,0.0,6.590999984741211,,,-1.3806703831267617,,,37.03724726769297,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-27,6.300000190734863,6.5,6.239999771118164,6.400000095367432,11860,0.0,0.0,6.582999992370605,,,-2.7798860278788107,,,34.39094348782524,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-28,6.340000152587891,6.429999828338623,6.199999809265137,6.400000095367432,19607,0.0,0.0,6.576999998092651,,,-2.691195115957881,,,34.39094348782524,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-07-29,6.400000095367432,6.650000095367432,6.21999979019165,6.480000019073486,15592,0.0,0.0,6.5550000190734865,,,-1.1441647563961566,,,38.46989027288264,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-01,6.309999942779541,6.349999904632568,6.0,6.349999904632568,30070,0.0,0.0,6.525,,,-2.68199379873459,,,34.69511247575787,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-02,6.260000228881836,6.389999866485596,6.260000228881836,6.349999904632568,5626,0.0,0.0,6.486000013351441,,,-2.0968256003533123,,,34.69511247575785,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-03,6.25,6.449999809265137,6.210000038146973,6.449999809265137,38490,0.0,0.0,6.465999984741211,,,-0.24745090494637467,,,39.95161629685118,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-04,6.199999809265137,7.369999885559082,6.199999809265137,7.0,23570,0.0,0.0,6.510999965667724,,,7.510367638008841,,,59.337733036361314,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-05,7.0,7.28000020980835,6.539999961853027,7.199999809265137,7892,0.0,0.0,6.570999956130981,,,9.572361243851113,,,63.90156177758226,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-08,7.199999809265137,7.199999809265137,6.710000038146973,6.789999961853027,21622,0.0,0.0,6.591999959945679,,,3.003640823884047,,,51.211961102707804,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-09,7.090000152587891,7.139999866485596,6.440000057220459,6.769999980926514,33295,0.0,0.0,6.61899995803833,,,2.2813117365985813,,,50.683234242961575,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-10,6.760000228881836,6.760000228881836,6.5,6.699999809265137,2861,0.0,0.0,6.648999929428101,,,0.7670308373942603,,,48.784786773636505,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-11,6.510000228881836,6.78000020980835,6.510000228881836,6.78000020980835,7366,0.0,0.0,6.686999940872193,,,1.3907622216013769,,,51.041816601269275,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-12,6.900000095367432,7.019999980926514,6.429999828338623,6.900000095367432,4308,0.0,0.0,6.728999948501587,,,2.5412416135316422,,,54.295467393799285,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-15,6.900000095367432,7.079999923706055,6.659999847412109,7.010000228881836,43982,0.0,0.0,6.794999980926514,,,3.1640949015279634,,,57.109346115485316,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-16,6.75,6.889999866485596,6.650000095367432,6.800000190734863,4605,0.0,0.0,6.840000009536743,,,-0.5847926717267449,,,50.69277497466506,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-17,6.659999847412109,7.090000152587891,6.5,6.730000019073486,11193,0.0,0.0,6.868000030517578,,,-2.0093187366175944,,,48.727451947567374,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-18,6.730000019073486,7.090000152587891,6.5,6.599999904632568,23661,0.0,0.0,6.828000020980835,,,-3.339193257874577,,,45.22107897232087,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-19,6.510000228881836,6.980000019073486,6.510000228881836,6.78000020980835,6190,0.0,0.0,6.786000061035156,6.752749991416931,,-0.08841513664665704,0.49239302003609153,,50.52927412900116,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-22,6.599999904632568,6.75,6.400000095367432,6.480000019073486,9049,0.0,0.0,6.755000066757202,6.730499994754791,,-4.071059140873292,0.36401563065900405,,43.042953193378686,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-23,6.940000057220459,6.940000057220459,6.480000019073486,6.5,18745,0.0,0.0,6.728000068664551,6.7082499980926515,,-3.3888238159576463,0.2944146473001916,,43.64242725429377,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-24,6.5,6.820000171661377,6.46999979019165,6.510000228881836,30218,0.0,0.0,6.709000110626221,6.6925000071525576,,-2.966163041631103,0.24654618537211498,,43.96003117846482,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-25,6.53000020980835,6.949999809265137,6.300000190734863,6.949999809265137,59971,0.0,0.0,6.726000070571899,6.6925000071525576,,3.3303558778314293,0.5005612758093229,,55.77061756392384,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-26,6.949999809265137,6.949999809265137,6.199999809265137,6.800000190734863,77095,0.0,0.0,6.716000080108643,6.690000009536743,,1.2507461230533794,0.3886408151694404,,51.76531770819856,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-29,6.579999923706055,6.900000095367432,6.449999809265137,6.900000095367432,28985,0.0,0.0,6.7050000667572025,6.678250014781952,,2.908277802665835,0.40055481474998356,,54.13041239056068,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-30,6.699999809265137,6.75,6.199999809265137,6.389999866485596,51951,0.0,0.0,6.664000034332275,6.665750014781952,,-4.11164715538802,-0.02625331651795497,,42.645706216340976,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-08-31,6.900000095367432,6.900000095367432,6.349999904632568,6.349999904632568,4745,0.0,0.0,6.626000022888183,6.660750007629394,,-4.165410765201147,-0.5217127906227889,,41.894924216846405,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-01,6.260000228881836,6.53000020980835,6.260000228881836,6.46999979019165,27004,0.0,0.0,6.613000011444091,6.650750005245209,,-2.1624107213817148,-0.5676050636596712,,45.02196600109899,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-02,6.599999904632568,6.599999904632568,6.28000020980835,6.449999809265137,20298,0.0,0.0,6.57999997138977,6.641999995708465,,-1.9756863630681156,-0.9334541457204817,,44.59123852081702,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-05,6.300000190734863,6.449999809265137,5.699999809265137,6.449999809265137,28826,0.0,0.0,6.576999950408935,6.634499990940094,,-1.9309737281646508,-0.8666823514911385,,44.591238520817015,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-06,6.449999809265137,6.670000076293945,6.039999961853027,6.570000171661377,31118,0.0,0.0,6.583999967575073,6.630499994754791,,-0.21263359633417714,-0.7013049878063936,,48.04974169766181,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-07,6.300000190734863,6.489999771118164,6.170000076293945,6.289999961853027,14565,0.0,0.0,6.561999940872193,6.62574999332428,,-4.145077437824731,-0.9621560203194764,,41.535165553631856,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-08,6.329999923706055,6.489999771118164,6.090000152587891,6.320000171661377,16749,0.0,0.0,6.498999977111817,6.6222499966621395,,-2.7542669038443064,-1.8611502074437747,,42.43569719078123,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-09,6.320000171661377,6.320000171661377,5.800000190734863,6.269999980926514,62520,0.0,0.0,6.445999956130981,6.611500000953674,,-2.7303750605376385,-2.5032147742391344,,41.29407079643207,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-12,5.960000038146973,6.199999809265137,5.909999847412109,6.0,24370,0.0,0.0,6.355999946594238,6.595249998569488,,-5.6010061294131255,-3.627611569343747,,35.7076829392732,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-13,6.199999809265137,6.320000171661377,5.869999885559082,6.0,22394,0.0,0.0,6.3169999599456785,6.576750004291535,,-5.018204241818683,-3.9495198110975975,,35.7076829392732,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-14,6.400000095367432,6.480000019073486,5.880000114440918,5.989999771118164,12115,0.0,0.0,6.280999946594238,6.560249996185303,,-4.6330230528638,-4.256698292800502,,35.501380576204085,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-15,5.989999771118164,6.320000171661377,5.989999771118164,6.190000057220459,1361,0.0,0.0,6.252999973297119,6.551249992847443,,-1.0075150543050675,-4.5525666075321265,,42.63916398307621,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-16,5.639999866485596,6.179999828338623,5.599999904632568,6.079999923706055,24964,0.0,0.0,6.215999984741211,6.53824999332428,,-2.1879031751770293,-4.928689005652802,,40.0161787837156,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-19,6.079999923706055,6.309999942779541,5.650000095367432,6.139999866485596,11880,0.0,0.0,6.184999990463257,6.527249991893768,,-0.7275686992246938,-5.243402686515056,,42.10810904206697,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-20,6.139999866485596,6.139999866485596,5.599999904632568,6.099999904632568,12933,0.0,0.0,6.137999963760376,6.517249989509582,,-0.6190951344438831,-5.819172601322056,,41.079543187434176,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-21,5.900000095367432,5.96999979019165,5.0,5.889999866485596,43444,0.0,0.0,6.097999954223633,6.504499983787537,,-3.4109558756879164,-6.2495200334707475,,36.09467196787396,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-22,5.849999904632568,5.849999904632568,5.440000057220459,5.550000190734863,25222,0.0,0.0,6.020999956130981,6.483249986171723,,-7.8226169876735305,-7.129912174089932,,29.79143573611742,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-23,5.010000228881836,5.840000152587891,5.010000228881836,5.739999771118164,46897,0.0,0.0,5.9679999351501465,6.464749979972839,,-3.820378125159049,-7.683979215925992,,36.46826154705374,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-26,5.75,5.78000020980835,5.449999809265137,5.78000020980835,11498,0.0,0.0,5.945999956130981,6.4504999876022335,,-2.791788556127846,-7.821099642522193,,37.809182012742596,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-27,5.78000020980835,5.789999961853027,5.449999809265137,5.769999980926514,12366,0.0,0.0,5.9229999542236325,6.4359999895095825,,-2.5831499996554284,-7.970789871381591,,37.595544003484434,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-28,5.5,6.0,5.449999809265137,5.860000133514404,67147,0.0,0.0,5.909999990463257,6.421249997615814,,-0.8460212695352921,-7.961845549423903,,40.835650774165025,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-29,5.849999904632568,5.900000095367432,5.489999771118164,5.75,39838,0.0,0.0,5.865999984741211,6.389999997615814,,-1.9774971879125962,-8.200313193585513,,38.223440431812385,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-09-30,5.820000171661377,5.849999904632568,5.590000152587891,5.840000152587891,14475,0.0,0.0,5.8420000076293945,6.356000006198883,,-0.034232369717428685,-8.086847043237796,,41.519639422575025,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-03,5.840000152587891,5.889999866485596,5.599999904632568,5.75,8398,0.0,0.0,5.803000020980835,6.330000007152558,,-0.9133210544410202,-8.32543421131503,,39.263512460044225,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-04,5.71999979019165,5.900000095367432,5.579999923706055,5.900000095367432,32467,0.0,0.0,5.783000040054321,6.30825001001358,,2.023172306808622,-8.326397481480422,,44.66080290077653,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-05,5.900000095367432,5.900000095367432,5.789999961853027,5.800000190734863,17935,0.0,0.0,5.774000072479248,6.285750019550323,,0.45029646569524395,-8.141430147228238,,41.98234083085302,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-06,5.889999866485596,8.119999885559082,5.889999866485596,6.75,177999,0.0,0.0,5.894000053405762,6.285000014305115,,14.523242939226158,-6.221160859338244,,64.04402489352,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-07,6.75,7.0,6.269999980926514,6.440000057220459,16899,0.0,0.0,5.964000082015991,6.27350001335144,,7.981220131767125,-4.933449122129001,,56.49468730137365,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-10,6.679999828338623,6.900000095367432,5.769999980926514,6.900000095367432,29086,0.0,0.0,6.076000070571899,6.270750010013581,,13.56155390429372,-3.1056881414614046,,63.39076064539391,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-11,6.989999771118164,7.0,6.480000019073486,6.570000171661377,11715,0.0,0.0,6.156000089645386,6.2650000095367435,,6.725147433190491,-1.7398231400707922,,56.474765656557146,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-12,6.570000171661377,6.570000171661377,6.25,6.380000114440918,14981,0.0,0.0,6.2080000877380375,6.256250011920929,,2.7706189476803127,-0.7712275578973639,,52.89644104476769,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-13,6.489999771118164,6.5,6.099999904632568,6.420000076293945,22373,0.0,0.0,6.275000095367432,6.251750016212464,,2.3107566330327396,0.3718971343171787,,53.563516787748725,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-14,6.489999771118164,6.5,6.21999979019165,6.46999979019165,6791,0.0,0.0,6.338000059127808,6.244000005722046,,2.0826716603408753,1.5054460813520112,,54.432220972812694,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-17,6.400000095367432,6.400000095367432,6.059999942779541,6.079999923706055,24712,0.0,0.0,6.371000051498413,6.23400000333786,,-4.567573778686711,2.197626693731146,,47.04019729929707,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-18,6.070000171661377,6.429999828338623,5.900000095367432,6.0,326208,0.0,0.0,6.38100004196167,6.2215000033378605,,-5.97085158213761,2.5636910477897135,,45.6701072154875,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-19,6.099999904632568,6.170000076293945,5.989999771118164,6.050000190734863,45376,0.0,0.0,6.40600004196167,6.210000002384186,,-5.557287681780773,3.156200314045643,,46.714716875702365,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-20,6.050000190734863,7.170000076293945,5.800000190734863,7.170000076293945,134529,0.0,0.0,6.448000049591064,6.215500009059906,,11.197270799473255,3.740649025697991,,63.598385946090566,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-21,7.119999885559082,7.650000095367432,7.0,7.5,117883,0.0,0.0,6.554000043869019,6.233000004291535,,14.433932709779624,5.150008653240329,,66.92386943299098,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-24,7.800000190734863,8.600000381469727,7.800000190734863,8.300000190734863,83732,0.0,0.0,6.6940000534057615,6.26800000667572,,23.991636159488884,6.796427030573243,,73.29347419057936,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-25,8.489999771118164,8.949999809265137,7.900000095367432,8.470000267028809,86377,0.0,0.0,6.884000062942505,6.320000016689301,,23.038933608149648,8.924051341200034,,74.42074780036401,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-26,8.470000267028809,8.470000267028809,7.599999904632568,7.929999828338623,38291,0.0,0.0,7.039000034332275,6.359500014781952,,12.658045029983702,10.684802546912504,,65.03084641866863,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-27,7.929999828338623,8.399999618530273,7.760000228881836,8.399999618530273,77603,0.0,0.0,7.236999988555908,6.4077500104904175,,16.0701897445551,12.941359708288994,,68.72909185587716,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-28,8.399999618530273,8.550000190734863,8.149999618530273,8.390000343322754,116485,0.0,0.0,7.429000043869019,6.456250023841858,,12.935796120324783,15.066795995120335,,68.56295893435501,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-10-31,8.510000228881836,8.510000228881836,7.849999904632568,8.100000381469727,30123,0.0,0.0,7.631000089645386,6.497500038146972,,6.145987240397681,17.445171909867,,63.750028516830746,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-01,7.909999847412109,8.25,7.849999904632568,7.989999771118164,17408,0.0,0.0,7.8300000667572025,6.533000028133392,,2.0434189399340004,19.853054232947695,,61.97296025679321,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-02,7.989999771118164,7.989999771118164,7.369999885559082,7.940000057220459,37906,0.0,0.0,8.019000053405762,6.574250030517578,,-0.9851601902876971,21.975891032158408,,61.13870856637774,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-03,7.940000057220459,8.1899995803833,7.5,7.75,30076,0.0,0.0,8.077000045776368,6.610000026226044,,-4.048533414920094,22.193646198635523,,57.94648815418587,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-04,7.699999809265137,8.079999923706055,7.599999904632568,8.079999923706055,8768,0.0,0.0,8.135000038146973,6.655250024795532,,-0.6760923685680381,22.23432640153745,,61.68807142336192,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-07,7.989999771118164,7.989999771118164,7.5,7.590000152587891,38797,0.0,0.0,8.064000034332276,6.695000028610229,,-5.877974698987384,20.448095591811793,,54.004706246020966,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-08,7.590000152587891,7.769999980926514,7.380000114440918,7.5,12172,0.0,0.0,7.9670000076293945,6.73250002861023,,-5.861679517788175,18.336427386157755,,52.706200009788034,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-09,7.989999771118164,7.989999771118164,7.5,7.5,25480,0.0,0.0,7.924000024795532,6.770250034332276,,-5.350833208843572,17.041467960747873,,52.706200009788034,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-10,8.390000343322754,8.390000343322754,7.230000019073486,7.5,40266,0.0,0.0,7.834000062942505,6.803000032901764,,-4.263467708181921,15.155079010061042,,52.70620000978802,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-11,7.130000114440918,7.900000095367432,7.130000114440918,7.449999809265137,11088,0.0,0.0,7.740000009536743,6.837250030040741,,-3.74677260871171,13.20340744494645,,51.84129044365326,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-14,7.789999961853027,7.800000190734863,7.320000171661377,7.320000171661377,10504,0.0,0.0,7.661999988555908,6.866750037670135,,-4.4635841478119,11.581169352650537,,49.56393942146996,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-15,7.320000171661377,7.769999980926514,7.150000095367432,7.21999979019165,12324,0.0,0.0,7.584999990463257,6.894750034809112,,-4.812131848787439,10.011239742837972,,47.82357417639475,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-16,7.21999979019165,7.579999923706055,7.21999979019165,7.349999904632568,16969,0.0,0.0,7.525999975204468,6.931250035762787,,-2.3385606052585457,8.580702418365847,,50.26832409547582,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-17,7.309999942779541,7.340000152587891,7.210000038146973,7.25,28378,0.0,0.0,7.475999975204468,6.973750030994415,,-3.0230066339491533,7.202006696222741,,48.39005936280625,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-18,7.25,7.480000019073486,7.110000133514404,7.300000190734863,8406,0.0,0.0,7.398000001907349,7.012750041484833,,-1.3246797938256163,5.493564694927376,,49.40795072140988,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-21,7.300000190734863,7.300000190734863,7.199999809265137,7.239999771118164,26210,0.0,0.0,7.362999963760376,7.0492500305175785,,-1.6705173604183208,4.450827136000464,,48.1799414498137,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-22,7.489999771118164,7.489999771118164,7.059999942779541,7.079999923706055,8222,0.0,0.0,7.320999956130981,7.082000029087067,,-3.2919004762880872,3.374751850639621,,44.970134208459136,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-23,7.079999923706055,7.5,7.010000228881836,7.389999866485596,15464,0.0,0.0,7.309999942779541,7.120250022411346,,1.0943902097437728,2.664933390975703,,51.686141190548184,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-24,7.349999904632568,7.400000095367432,7.260000228881836,7.260000228881836,18032,0.0,0.0,7.285999965667725,7.158000028133392,,-0.35684514010982576,1.7882081172289634,,48.98621565294579,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-25,7.260000228881836,7.449999809265137,7.0,7.190000057220459,20935,0.0,0.0,7.259999990463257,7.191750025749206,,-0.9641864095695569,0.9490035731176661,,47.545981385403444,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-28,7.179999828338623,7.78000020980835,7.0,7.139999866485596,29239,0.0,0.0,7.241999959945678,7.226500022411346,,-1.4084520025438905,0.21448747645834865,,46.49446097633797,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-29,7.199999809265137,7.199999809265137,6.949999809265137,7.199999809265137,26108,0.0,0.0,7.2399999618530275,7.259000015258789,,-0.5524882983238724,-0.26174477704673693,,47.981177825803435,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-11-30,7.210000038146973,7.210000038146973,7.0,7.0,6324,0.0,0.0,7.20499997138977,7.289000010490417,,-2.845245970906339,-1.1524219917650285,,43.629350122047704,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-01,7.0,7.25,6.920000076293945,7.25,23872,0.0,0.0,7.20499997138977,7.301500010490417,,0.624566672989863,-1.3216467706909636,,49.763007719757766,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-02,6.909999847412109,7.940000057220459,6.909999847412109,7.690000057220459,38409,0.0,0.0,7.24399995803833,7.332750010490417,,6.1568208416017915,-1.2103242620451966,,58.35225959251911,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-05,7.400000095367432,7.670000076293945,7.210000038146973,7.320000171661377,5421,0.0,0.0,7.251999998092652,7.343250012397766,,0.9376747598815494,-1.2426379893242732,,50.52871593777865,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-06,7.46999979019165,7.46999979019165,7.099999904632568,7.309999942779541,13571,0.0,0.0,7.275,7.36175000667572,,0.4810988698218647,-1.1783883804401662,,50.332295982522446,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-07,7.199999809265137,7.440000057220459,7.070000171661377,7.150000095367432,3243,0.0,0.0,7.251000022888183,7.381000006198883,,-1.3929103186034992,-1.76127873189975,,47.17269427801889,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-08,7.349999904632568,7.389999866485596,7.019999980926514,7.150000095367432,9026,0.0,0.0,7.240000009536743,7.39925000667572,,-1.2430927355077481,-2.152245119374245,,47.17269427801889,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-09,7.239999771118164,7.239999771118164,6.989999771118164,7.0,12968,0.0,0.0,7.221000003814697,7.412500011920929,6.803083336353302,-3.0605179850152,-2.5834739669242173,8.957948116130185,44.158694886218235,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-12,7.190000057220459,7.28000020980835,6.920000076293945,6.929999828338623,13593,0.0,0.0,7.2,7.433750009536743,6.799416669209799,-3.7500023841857932,-3.1444427003445803,9.329231773652488,42.78485906002645,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-13,7.090000152587891,7.090000152587891,6.739999771118164,6.989999771118164,79295,0.0,0.0,7.178999996185302,7.458500003814697,6.796083335081736,-2.632681782526357,-3.7474023930608364,9.747035697951665,44.382097055126806,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-14,7.0,7.0,6.75,6.75,29865,0.0,0.0,7.153999996185303,7.4759999990463255,6.792833336194357,-5.647190332691167,-4.3071161436877805,10.057168033430786,39.61785034861495,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-15,6.75,6.989999771118164,6.400000095367432,6.989999771118164,19395,0.0,0.0,7.127999973297119,7.471499991416931,6.793166669209798,-1.936029779684778,-4.597470635272918,9.98552450187475,45.874902808938174,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-16,6.989999771118164,7.489999771118164,6.650000095367432,6.980000019073486,25545,0.0,0.0,7.056999969482422,7.458499991893769,6.793833335240682,-1.0911145067580712,-5.383120236612123,9.78338183842922,45.662585786826774,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-19,6.610000133514404,6.900000095367432,6.400000095367432,6.579999923706055,27144,0.0,0.0,6.98299994468689,7.415499985218048,6.78725000222524,-5.771158874023239,-5.8323786850960495,9.256325946249703,38.07206407613516,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-20,6.579999923706055,6.690000057220459,6.110000133514404,6.5,29093,0.0,0.0,6.9019999504089355,7.366249978542328,6.7840000033378605,-5.824398048352891,-6.302393069550168,8.58269420574866,36.75606876375271,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-21,6.420000076293945,6.96999979019165,6.239999771118164,6.659999847412109,12048,0.0,0.0,6.852999925613403,7.334499979019165,6.784916667143504,-2.8162860104513827,-6.564865427542786,8.100074604262455,41.13830102731633,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-22,6.659999847412109,6.659999847412109,6.25,6.460000038146973,2879,0.0,0.0,6.783999919891357,7.285999989509582,6.781500001748403,-4.7759417094682615,-6.889926850686341,7.439356892001911,37.628458308256405,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-23,6.599999904632568,7.389999866485596,6.460000038146973,7.28000020980835,7709,0.0,0.0,6.811999940872193,7.258249986171722,6.785500001907349,6.870233015243321,-6.148176849098839,6.967061883891936,54.695312782451204,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-27,7.199999809265137,7.440000057220459,6.699999809265137,7.429999828338623,14800,0.0,0.0,6.861999940872193,7.241499972343445,6.791166667143504,8.277468556699448,-5.24062739654256,6.631162615677056,57.012545390505544,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-28,7.400000095367432,7.440000057220459,6.5,7.090000152587891,74271,0.0,0.0,6.871999979019165,7.218999981880188,6.794166668256124,3.1722958998006368,-4.806759990746625,6.252912746591586,50.684433840354345,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-29,6.699999809265137,7.199999809265137,6.659999847412109,7.0,10858,0.0,0.0,6.896999979019165,7.195499980449677,6.7985000014305115,1.4934032375549233,-4.1484261307976125,5.83952311444628,49.129904090633005,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2022-12-30,7.389999866485596,7.389999866485596,6.480000019073486,7.039999961853027,41594,0.0,0.0,6.901999998092651,7.177749979496002,6.8033333341280615,1.9994199333310936,-3.8417328855290265,5.503429377621801,49.86587206728559,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-02,7.099999904632568,7.139999866485596,6.800000190734863,7.050000190734863,16754,0.0,0.0,6.909000015258789,7.151999986171722,6.806250003973643,2.0408188618420953,-3.3976506065823537,5.079889542644221,50.06039754408598,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-03,6.840000152587891,7.389999866485596,6.840000152587891,6.900000095367432,26928,0.0,0.0,6.941000032424927,7.134749984741211,6.808333337306976,-0.5906920741386468,-2.715581523257982,4.794369359760927,47.10781362449139,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-04,7.150000095367432,7.210000038146973,6.840000152587891,7.0,12700,0.0,0.0,6.991000032424926,7.122249984741211,6.810500005880992,0.1287364830972806,-1.842815860121117,4.577490325101205,49.25653834812741,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-05,7.099999904632568,7.25,6.880000114440918,7.25,12461,0.0,0.0,7.0500000476837155,7.115999984741211,6.815500005086263,2.8368787370717072,-0.9274864699131323,4.409067264774278,54.25937644499303,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-09,6.949999809265137,7.309999942779541,6.949999809265137,7.039999961853027,28897,0.0,0.0,7.108000040054321,7.104499983787536,6.819583336512248,-0.9566696372834329,0.049265342737306934,4.177918697024148,49.81641188258524,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-10,7.119999885559082,7.309999942779541,6.889999866485596,7.099999904632568,16519,0.0,0.0,7.090000009536743,7.095749986171723,6.8237500031789144,0.14104224375704816,-0.08103409288919988,3.986077785178152,51.04971387034125,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-11,7.380000114440918,7.440000057220459,6.599999904632568,7.159999847412109,22479,0.0,0.0,7.063000011444092,7.091749978065491,6.8285833358764645,1.3733517741873158,-0.4054001721764278,3.853898081705821,52.31184060229221,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-12,7.159999847412109,7.159999847412109,6.860000133514404,6.980000019073486,18087,0.0,0.0,7.0519999980926515,7.085749983787537,6.832583336035411,-1.020986656815641,-0.47630788232870647,3.70528444807854,48.28926458494873,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-13,7.099999904632568,7.590000152587891,6.949999809265137,7.190000057220459,10353,0.0,0.0,7.071000003814698,7.081749987602234,6.839166669050853,1.6829310329735911,-0.1517984086752011,3.5469718796171326,52.845052428076386,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-16,7.190000057220459,7.389999866485596,6.699999809265137,7.110000133514404,51882,0.0,0.0,7.078000020980835,7.078249990940094,6.845083336035411,0.45210670300527545,-0.0035315220510551072,3.406337709245925,51.00164290853447,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-17,7.03000020980835,7.170000076293945,6.949999809265137,7.150000095367432,17927,0.0,0.0,7.088000011444092,7.074499988555909,6.850666670004527,0.8747190155648423,0.1908265306385155,3.2673216977762216,51.90502583081803,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-18,6.900000095367432,7.78000020980835,6.599999904632568,7.78000020980835,93928,0.0,0.0,7.176000022888184,7.087999999523163,6.862583339214325,8.416947951416933,1.2415353184387867,3.284720187232657,63.36236006718951,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-19,8.0,8.0,6.949999809265137,7.199999809265137,45413,0.0,0.0,7.196000003814698,7.0909999966621395,6.869666671752929,0.05558373330070521,1.4807503483568392,3.221893222553296,51.25628503238245,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-20,7.199999809265137,7.260000228881836,7.150000095367432,7.230000019073486,8569,0.0,0.0,7.194000005722046,7.087000000476837,6.8761666735013325,0.5004171993717865,1.5098067622126372,3.066146255412807,51.76958787706514,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-23,7.949999809265137,7.949999809265137,7.21999979019165,7.400000095367432,15169,0.0,0.0,7.230000019073486,7.090499997138977,6.879500007629394,2.35131501860951,1.9674215075212984,3.067083207727059,54.681889468463915,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-24,7.650000095367432,7.650000095367432,7.139999866485596,7.320000171661377,11046,0.0,0.0,7.252000045776367,7.09375,6.880500010649363,0.9376740961910707,2.2308376497109057,3.0993385512764684,53.05823608340615,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-25,7.300000190734863,7.989999771118164,7.300000190734863,7.329999923706055,58311,0.0,0.0,7.269000053405762,7.098500001430511,6.8850000103314715,0.8391782893399837,2.401916629441301,3.100943947402566,53.24511535869978,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-26,7.800000190734863,7.800000190734863,7.329999923706055,7.400000095367432,25796,0.0,0.0,7.311000061035156,7.103500008583069,6.890250011285146,1.217344188062745,2.921095969611711,3.0949529690309165,54.6074410892854,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-27,7.389999866485596,7.389999866485596,7.130000114440918,7.300000190734863,23863,0.0,0.0,7.3220000743865965,7.111000013351441,6.89525001446406,-0.30046276192610216,2.967234715778193,3.1289655695559278,52.264579696145255,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-30,7.300000190734863,7.559999942779541,7.159999847412109,7.409999847412109,28076,0.0,0.0,7.352000045776367,7.115000009536743,6.900500011444092,0.7888982763141104,3.3309913692474455,3.1084703678996446,54.57335597110571,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-01-31,7.400000095367432,7.400000095367432,6.989999771118164,7.300000190734863,49693,0.0,0.0,7.3670000553131105,7.1052500128746034,6.903833345572154,-0.909459265307412,3.6838963015266177,2.9174613178000666,51.87154496255572,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-01,7.300000190734863,7.300000190734863,7.0,7.170000076293945,35625,0.0,0.0,7.30600004196167,7.101500010490417,6.905166677633921,-1.8614832314072678,2.879673747365526,2.8432815893123453,48.79684237268518,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-02,7.300000190734863,7.300000190734863,6.940000057220459,7.099999904632568,20531,0.0,0.0,7.296000051498413,7.096250009536743,6.907666675249735,-2.686405502773963,2.814867594760935,2.730058399643181,47.175298725960175,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-03,7.099999904632568,7.309999942779541,6.909999847412109,7.150000095367432,37172,0.0,0.0,7.288000059127808,7.096250009536743,6.911166675885519,-1.893523087826255,2.7021321026368725,2.678033135809303,48.49194558759172,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-06,7.199999809265137,7.5,7.199999809265137,7.449999809265137,39427,0.0,0.0,7.293000030517578,7.103750002384186,6.918250008424123,2.15274616880012,2.6640862652806647,2.681313825522142,55.63673769204628,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-07,7.489999771118164,7.5,7.269999980926514,7.5,7941,0.0,0.0,7.311000013351441,7.116250002384186,6.92425000667572,2.5851454835645606,2.7366943390410223,2.7728634223685935,56.71442591360729,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-08,7.5,7.550000190734863,7.159999847412109,7.400000095367432,23082,0.0,0.0,7.318000030517578,7.128000009059906,6.9319166739781695,1.1205256150300091,2.6655446298565746,2.8287030024151427,53.89456776039351,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-09,7.210000038146973,7.909999847412109,7.110000133514404,7.699999809265137,23705,0.0,0.0,7.348000001907349,7.145750010013581,6.941916672388713,4.790416538737316,2.830353589341194,2.936268861244181,60.27567681544341,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-10,7.699999809265137,7.699999809265137,7.119999885559082,7.599999904632568,9718,0.0,0.0,7.377999973297119,7.167000007629395,6.951000003019969,3.008944593913309,2.944048631827983,3.10746661653836,57.42274465686466,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-13,7.599999904632568,7.599999904632568,7.210000038146973,7.289999961853027,7279,0.0,0.0,7.365999984741211,7.1745000123977665,6.953833337624868,-1.0317678936413075,2.6691751622067903,3.173309799919202,49.58725521628738,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-14,7.21999979019165,7.440000057220459,7.010000228881836,7.139999866485596,6056,0.0,0.0,7.349999952316284,7.178500008583069,6.956666668256124,-2.8571440434432755,2.3890777116132726,3.1887878333913906,46.29544314618329,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-15,7.139999866485596,7.199999809265137,7.0,7.199999809265137,4516,0.0,0.0,7.352999925613403,7.194000005722046,6.959166665871938,-2.0807849571071904,2.2101740306490165,3.3744462681392764,47.788495899073126,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-16,7.21999979019165,7.329999923706055,6.920000076293945,7.329999923706055,14842,0.0,0.0,7.375999927520752,7.214750003814697,6.966999999682108,-0.6236443094727491,2.235003619263258,3.556050009242051,50.969112706893114,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-17,7.079999923706055,7.300000190734863,6.900000095367432,7.269999980926514,22554,0.0,0.0,7.3879999160766605,7.230000007152557,6.974666666984558,-1.597183764084418,2.185337603980578,3.660868000712502,49.471190391594874,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-20,7.119999885559082,7.269999980926514,7.0,7.090000152587891,17220,0.0,0.0,7.351999950408936,7.24575001001358,6.979833336671193,-3.5636534220388842,1.4663760169550242,3.809785427759331,45.181293844515025,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-21,7.070000171661377,7.070000171661377,6.800000190734863,6.900000095367432,7752,0.0,0.0,7.291999959945679,7.236250007152558,6.98358333905538,-5.37575242363506,0.7704260181449808,3.618008919348767,41.12723289957801,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-22,6.820000171661377,7.079999923706055,6.809999942779541,6.869999885559082,6480,0.0,0.0,7.238999938964843,7.222250008583069,6.9870833396911625,-5.0973899228755535,0.23192122069809595,3.3657344196255345,40.50915945423566,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-23,7.409999847412109,7.409999847412109,7.010000228881836,7.389999866485596,9554,0.0,0.0,7.20799994468689,7.229750001430512,6.993916670481364,2.5249711875048026,-0.30084106282124023,3.3719779925961877,53.54190020369238,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-24,7.28000020980835,7.28000020980835,6.75,6.96999979019165,29537,0.0,0.0,7.144999933242798,7.228999996185303,6.999583335717519,-2.4492672454333086,-1.161987314799161,3.2775759565160865,44.97228485375299,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-27,6.96999979019165,7.190000057220459,6.730000019073486,6.900000095367432,5323,0.0,0.0,7.105999946594238,7.225499999523163,7.00441666841507,-2.8989565546723397,-1.6538655170827068,3.1563417993824014,43.71641805328114,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-02-28,6.880000114440918,7.199999809265137,6.789999961853027,6.900000095367432,23419,0.0,0.0,7.081999969482422,7.221749997138977,7.009666669368744,-2.5698937432824023,-1.9351269112323062,3.025583637193581,43.71641805328114,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-01,6.900000095367432,7.099999904632568,6.75,7.099999904632568,4175,0.0,0.0,7.071999979019165,7.226749992370605,7.018833335240682,0.39592655113789366,-2.141350033068972,2.962268046542713,48.48345137955198,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-02,7.119999885559082,7.179999828338623,6.75,6.929999828338623,7119,0.0,0.0,7.031999969482422,7.224999988079071,7.02658333381017,-1.4505139588518332,-2.671280538617171,2.823799915873333,44.99498315692103,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-03,7.050000190734863,7.050000190734863,6.710000038146973,6.860000133514404,8066,0.0,0.0,6.990999984741211,7.215249991416931,7.033833336830139,-1.8738356674686183,-3.10800051200557,2.5792003577461577,43.60375969153933,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-06,6.75,6.809999942779541,6.53000020980835,6.679999828338623,14243,0.0,0.0,6.9499999523162845,7.206249988079071,7.037916668256124,-3.8848938968363056,-3.5559415255741538,2.39180609486609,40.16470443266486,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-07,6.869999885559082,6.869999885559082,6.269999980926514,6.400000095367432,22067,0.0,0.0,6.899999952316284,7.188749992847443,7.040583336353302,-7.246374788466564,-4.016693316897311,2.1044656304130065,35.47727702587838,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-08,6.400000095367432,6.579999923706055,6.260000228881836,6.349999904632568,32481,0.0,0.0,6.847999954223633,7.168499994277954,7.042333336671193,-7.272197034462797,-4.470949854364938,1.79154623297621,34.69852406855975,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-09,6.489999771118164,6.5,6.230000019073486,6.5,17463,0.0,0.0,6.758999967575074,7.156499993801117,7.045666670799255,-3.8319273386236605,-5.554391484250035,1.5730707707364373,39.022875004690235,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-10,6.150000095367432,6.690000057220459,6.150000095367432,6.46999979019165,9481,0.0,0.0,6.708999967575073,7.138499987125397,7.050500003496806,-3.5623815552022973,-6.016670453525901,1.2481381970774554,38.474113054288274,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-13,6.150000095367432,6.46999979019165,6.099999904632568,6.28000020980835,34126,0.0,0.0,6.646999979019165,7.117749989032745,7.0565833369890845,-5.521284344354255,-6.613747472711553,0.8668026596247866,35.10690249660003,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-14,6.010000228881836,6.460000038146973,6.0,6.070000171661377,24739,0.0,0.0,6.563999986648559,7.090749990940094,7.059333340326945,-7.525896038878699,-7.428692380419102,0.44503707501216,31.7947626869272,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-15,6.139999866485596,6.610000133514404,6.0,6.449999809265137,24151,0.0,0.0,6.498999977111817,7.057499980926513,7.064916670322418,-0.7539647333320337,-7.913567202608427,-0.1049791489694446,42.38694700424253,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-16,6.159999847412109,6.539999961853027,6.150000095367432,6.179999828338623,28753,0.0,0.0,6.423999977111817,7.0319999814033505,7.0683333357175195,-3.7982588674119864,-8.64618893486114,-0.5140300066292898,37.88500043742702,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-17,6.179999828338623,6.539999961853027,6.179999828338623,6.199999809265137,7200,0.0,0.0,6.35799994468689,7.006249976158142,7.071166666348775,-2.4850603459628413,-9.252453647489158,-0.9180478024873487,38.406856937266085,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-20,6.199999809265137,6.690000057220459,5.730000019073486,6.630000114440918,10056,0.0,0.0,6.352999973297119,6.986999976634979,7.078500000635783,4.360147053487863,-9.073994639444695,-1.2926470861423394,48.437184178893965,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-21,6.619999885559082,6.619999885559082,5.989999771118164,6.079999923706055,64616,0.0,0.0,6.320999956130981,6.955999970436096,7.080499998728434,-3.8126884052763077,-9.128809905174636,-1.7583507988799694,39.562628251829615,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-22,6.010000228881836,6.110000133514404,5.860000133514404,5.960000038146973,61305,0.0,0.0,6.281999969482422,6.9217499732971195,7.082249999046326,-5.1257550604856075,-9.242604923360984,-2.266229316542322,37.92976228063902,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-23,6.090000152587891,6.090000152587891,5.880000114440918,5.909999847412109,2236,0.0,0.0,6.222999954223633,6.884499967098236,7.082333330313364,-5.029730180201695,-9.608541158195692,-2.7933359528331465,37.240076175601054,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-24,5.900000095367432,6.190000057220459,5.78000020980835,5.800000190734863,15162,0.0,0.0,6.155999994277954,6.846999967098236,7.082333330313364,-5.782972772482047,-10.092010751288626,-3.3228224688023182,35.70203256663609,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-27,5.800000190734863,6.190000057220459,5.800000190734863,6.070000171661377,2378,0.0,0.0,6.134999990463257,6.813499975204468,7.07666666507721,-1.0594917506588573,-9.95817108990082,-3.7187944879677444,42.030712581449116,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-28,6.190000057220459,6.190000057220459,5.829999923706055,5.880000114440918,19276,0.0,0.0,6.115999984741211,6.777999973297119,7.07199999888738,-3.8587290858255088,-9.766892758394066,-4.157240181511812,39.11319258438868,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-29,6.190000057220459,6.190000057220459,5.699999809265137,6.139999866485596,66343,0.0,0.0,6.084999990463257,6.752249968051911,7.065666663646698,0.9038599196144205,-9.881890936291295,-4.435769623938474,44.76355959285298,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-30,5.699999809265137,6.190000057220459,5.699999809265137,6.0,18370,0.0,0.0,6.067000007629394,6.724749970436096,7.0609166622161865,-1.1043350510159897,-9.781032242066349,-4.760949716046911,42.47767867928479,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-03-31,5.670000076293945,6.550000190734863,5.670000076293945,6.230000019073486,13332,0.0,0.0,6.070000028610229,6.701749968528747,7.059666661421458,2.6359141632473824,-9.42664144268587,-5.06988091730445,47.24402479886309,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-03,6.21999979019165,6.21999979019165,5.800000190734863,6.079999923706055,19130,0.0,0.0,6.0150000095367435,6.667499971389771,7.056833326816559,1.0806303252910094,-9.78627618527039,-5.517111392546125,44.64579205624165,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-04,6.079999923706055,6.400000095367432,5.900000095367432,6.340000152587891,19401,0.0,0.0,6.041000032424927,6.638499975204468,7.055749996503194,4.949513632810583,-9.00052639920568,-5.913616858668663,49.79935234763185,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-05,6.260000228881836,6.28000020980835,5.940000057220459,6.21999979019165,13429,0.0,0.0,6.067000007629394,6.608999967575073,7.056916662057241,2.5218358722573826,-8.200937548870133,-6.347201135170991,47.59679152946108,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-06,5.820000171661377,6.300000190734863,5.820000171661377,6.300000190734863,16894,0.0,0.0,6.10600004196167,6.573999977111816,7.059416663646698,3.1772051660659253,-7.118952491322565,-6.876158607191907,49.209590422585066,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-11,6.199999809265137,6.300000190734863,6.179999828338623,6.300000190734863,28357,0.0,0.0,6.15600004196167,6.541499984264374,7.061499996980031,2.339183687323464,-5.8931429065203185,-7.363874714126519,49.20959042258507,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-12,6.300000190734863,6.699999809265137,6.199999809265137,6.400000095367432,21600,0.0,0.0,6.189000034332276,6.519249987602234,7.055083330472311,3.409275486583843,-5.06576606048242,-7.594996653770276,51.37891136178909,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-13,6.400000095367432,6.400000095367432,6.139999866485596,6.400000095367432,1707,0.0,0.0,6.241000032424926,6.50074999332428,7.045916664600372,2.547669638141728,-3.9956922073006105,-7.737342026979722,51.37891136178909,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-14,6.139999866485596,6.400000095367432,6.079999923706055,6.340000152587891,35516,0.0,0.0,6.261000061035157,6.4792500019073485,7.029583330949148,1.2617807184571823,-3.368444508360441,-7.828818624552706,49.89595606683894,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-17,6.119999885559082,6.539999961853027,6.119999885559082,6.5,21011,0.0,0.0,6.311000061035156,6.458500003814697,7.013166662057241,2.9947700386148153,-2.283811143336998,-7.90893308216118,53.73113330144067,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-18,6.21999979019165,6.480000019073486,6.079999923706055,6.320000171661377,38234,0.0,0.0,6.320000076293946,6.434750008583069,6.999749998251597,1.508978324906559e-06,-1.7832850093020307,-8.071716701448691,49.17117903409771,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-19,6.099999904632568,6.099999904632568,5.900000095367432,6.099999904632568,22700,0.0,0.0,6.3220000743865965,6.410000002384185,6.980583333969117,-3.5115496226179355,-1.372853790403394,-8.173863190033732,44.23044377688067,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-20,6.179999828338623,6.179999828338623,5.639999866485596,5.840000152587891,77357,0.0,0.0,6.272000074386597,6.383500003814698,6.959333332379659,-6.887753773519459,-1.7466895803473022,-8.274259919204964,39.21542773065039,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-21,5.840000152587891,5.840000152587891,5.699999809265137,5.820000171661377,21147,0.0,0.0,6.232000112533569,6.357250010967254,6.9403333306312565,-6.6110387264530575,-1.970189912581843,-8.401373419494938,38.85051489463148,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-24,5.800000190734863,6.059999942779541,5.659999847412109,5.920000076293945,36857,0.0,0.0,6.194000101089477,6.320500016212463,6.923083333174388,-4.423636104677127,-2.0014225899613365,-8.703973185970975,41.76825545558312,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-25,6.099999904632568,6.099999904632568,5.900000095367432,6.0,3896,0.0,0.0,6.164000082015991,6.296250021457672,6.906916666030884,-2.660611288673983,-2.1004556520305235,-8.841378492034659,44.06753867426592,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-26,6.199999809265137,6.199999809265137,5.940000057220459,6.019999980926514,18232,0.0,0.0,6.1260000705719,6.274250018596649,6.892499999205271,-1.7303311855086274,-2.3628313756280312,-8.969894532896753,44.65587931911862,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-27,6.019999980926514,6.139999866485596,5.900000095367432,6.039999961853027,7502,0.0,0.0,6.090000057220459,6.252750015258789,6.8754999995231625,-0.8210196206509162,-2.6028540664693995,-9.05752286099285,45.27578998044064,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-04-28,6.199999809265137,6.199999809265137,5.71999979019165,6.0,45920,0.0,0.0,6.05600004196167,6.225250017642975,6.862249998251597,-0.9247034605952565,-2.7187659162545135,-9.282669398097134,44.20923009684487,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-02,5.71999979019165,5.980000019073486,5.71999979019165,5.800000190734863,17095,0.0,0.0,5.986000061035156,6.197000026702881,6.8480833331743876,-3.1072480521847523,-3.404872757116758,-9.50752604480502,39.23274618702547,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-03,5.699999809265137,5.880000114440918,5.539999961853027,5.880000114440918,28408,0.0,0.0,5.942000055313111,6.172500026226044,6.8345833341280615,-1.0434187192030526,-3.7343048996933614,-9.687251958666542,42.0430905921265,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-04,5.880000114440918,6.0,5.5,5.679999828338623,62442,0.0,0.0,5.900000047683716,6.1475000262260435,6.819416666030884,-3.728817246899226,-4.026026473956244,-9.852992898231532,37.387811648330924,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-05,5.679999828338623,5.880000114440918,5.480000019073486,5.659999847412109,13265,0.0,0.0,5.8820000171661375,6.129000020027161,6.8044999996821085,-3.7742293285640724,-4.030021244149527,-9.927253724542664,36.94723982054187,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-08,5.659999847412109,5.980000019073486,5.639999866485596,5.840000152587891,17008,0.0,0.0,5.884000015258789,6.1162500262260435,6.7921666661898294,-0.747788282746349,-3.797261556858906,-9.951414227338914,43.41048982095035,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-09,5.559999942779541,5.840000152587891,5.5,5.699999809265137,28819,0.0,0.0,5.861999988555908,6.0962500214576725,6.779499999682108,-2.763564988178717,-3.8425266693007583,-10.078176535975713,39.97800582067842,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-10,5.699999809265137,5.699999809265137,5.300000190734863,5.559999942779541,23673,0.0,0.0,5.817999982833863,6.073500025272369,6.764583333333333,-4.434514280088629,-4.206800714173842,-10.216199195234458,36.84091263316197,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-11,5.940000057220459,5.940000057220459,5.400000095367432,5.480000019073486,10147,0.0,0.0,5.763999986648559,6.053500020503998,6.749833333492279,-4.927133383638383,-4.782357857022618,-10.31630380461567,35.14383362440945,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-12,5.440000057220459,5.480000019073486,5.019999980926514,5.360000133514404,27971,0.0,0.0,5.696000003814698,6.035750019550323,6.733666666348776,-5.898874123512449,-5.628961017854378,-10.364585617019955,32.70980553309825,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-15,5.300000190734863,5.320000171661377,4.699999809265137,5.119999885559082,30517,0.0,0.0,5.607999992370606,6.0025000214576725,6.716000000635783,-8.701856410046764,-6.572262018772385,-10.62388295280771,28.46376327035307,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-16,5.0,5.5,4.989999771118164,5.21999979019165,25355,0.0,0.0,5.549999952316284,5.978500020503998,6.700499999523163,-5.945948918196093,-7.167350785617134,-10.77531496262287,32.40123707506156,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-17,6.0,6.0,5.300000190734863,5.300000190734863,2837,0.0,0.0,5.491999959945678,5.956000030040741,6.683083335558574,-3.495989996560636,-7.790464535841997,-10.879458911566347,35.46169492397338,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-19,5.300000190734863,5.960000038146973,4.849999904632568,5.320000171661377,8528,0.0,0.0,5.4559999942779545,5.923250031471253,6.66691666841507,-2.492665373152657,-7.888406444278358,-11.154581254434808,36.23888219623067,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-22,5.320000171661377,5.320000171661377,4.940000057220459,5.099999904632568,4576,0.0,0.0,5.4,5.898750030994416,6.649500000476837,-5.55555732161911,-8.455181663467364,-11.290322120890066,31.714636591160996,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-23,4.940000057220459,5.099999904632568,4.940000057220459,5.059999942779541,1850,0.0,0.0,5.321999979019165,5.8762500286102295,6.632166667779287,-4.922961993094752,-9.432036535078273,-11.397732853148701,30.957867357348164,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-24,5.059999942779541,5.059999942779541,4.599999904632568,4.800000190734863,30113,0.0,0.0,5.232000017166138,5.848500037193299,6.612166670958201,-8.256877389409171,-10.541164676524813,-11.549415974631442,26.526989888811116,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-25,4.800000190734863,4.809999942779541,4.510000228881836,4.550000190734863,55028,0.0,0.0,5.13100004196167,5.817250037193299,6.591750005880992,-11.323325793711753,-11.796811050651177,-11.74953491859831,23.10295627499785,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-26,4.550000190734863,4.550000190734863,4.059999942779541,4.46999979019165,39330,0.0,0.0,5.030000019073486,5.777250027656555,6.568583337465922,-11.133205303346827,-12.934354667114489,-12.04724472772928,22.11905081609433,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-29,4.46999979019165,4.849999904632568,4.449999809265137,4.71999979019165,26451,0.0,0.0,4.965999984741211,5.748250019550324,6.543833335240682,-4.953688991249171,-13.608490099571322,-12.157756393425881,31.881984349600145,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-30,4.630000114440918,4.980000019073486,4.400000095367432,4.769999980926514,8292,0.0,0.0,4.930999994277954,5.714000022411346,6.522583333651225,-3.2650580721611955,-13.703185597870556,-12.396672757989101,33.672824955140754,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-05-31,4.760000228881836,4.760000228881836,4.159999847412109,4.230000019073486,44148,0.0,0.0,4.832000017166138,5.669750022888183,6.496916667620341,-12.458609187789516,-14.77578380599034,-12.731680073020362,25.787620385728374,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-01,4.329999923706055,4.53000020980835,4.329999923706055,4.340000152587891,13127,0.0,0.0,4.736000013351441,5.622500026226044,6.473500001430511,-8.36148352295548,-15.767007714353776,-13.145902139745324,29.41370524985527,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-02,4.409999847412109,4.409999847412109,4.110000133514404,4.179999828338623,16249,0.0,0.0,4.621999979019165,5.5750000238418576,6.448749999205272,-9.562963061162517,-17.09417113447757,-13.549137049367598,27.322510222349933,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-05,4.179999828338623,4.179999828338623,3.799999952316284,3.880000114440918,76233,0.0,0.0,4.5,5.513500022888183,6.4227500001589455,-13.777775234646267,-18.382153236253604,-14.156708220750621,23.892530091702923,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-07,3.880000114440918,4.699999809265137,3.880000114440918,4.699999809265137,65690,0.0,0.0,4.46399998664856,5.47550002336502,6.404166666666667,5.2867343934236635,-18.473199386360953,-14.500975562289858,44.427997327362604,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-08,4.599999904632568,4.599999904632568,3.7699999809265137,4.150000095367432,127540,0.0,0.0,4.398999977111816,5.421750020980835,6.380500002702077,-5.66037469970315,-18.863836213606834,-15.02625156829749,37.181366917918155,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-09,4.150000095367432,4.369999885559082,4.0,4.159999847412109,31423,0.0,0.0,4.359999942779541,5.368250012397766,6.358916668097178,-4.587158210830836,-18.7817271418006,-15.5791734253982,37.38135058259011,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-12,4.5,4.5,4.099999904632568,4.150000095367432,41212,0.0,0.0,4.3279999732971195,5.312000012397766,6.335250004132589,-4.112751363861158,-18.52409707838991,-16.151690794638572,37.25363046018582,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-13,4.099999904632568,4.099999904632568,3.9000000953674316,4.010000228881836,42856,0.0,0.0,4.2570000171661375,5.252250015735626,6.310500005880992,-5.802203131037994,-18.949021763772507,-16.769669426497785,35.42855489964232,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-14,4.010000228881836,4.53000020980835,4.010000228881836,4.489999771118164,19249,0.0,0.0,4.228999996185303,5.206000006198883,6.293083337942759,6.171666473594025,-18.766807699774247,-17.274256089849427,45.319592924012326,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-15,4.489999771118164,4.5,4.269999980926514,4.489999771118164,5193,0.0,0.0,4.25499997138977,5.1557500004768375,6.27633333603541,5.522909548966181,-17.470785608374342,-17.854108052623204,45.319592924012326,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-16,4.460000038146973,4.760000228881836,4.460000038146973,4.5,40889,0.0,0.0,4.270999956130981,5.110249996185303,6.2583333373069765,5.361743063010134,-16.42287638923349,-18.344873614797027,45.52122849749267,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-19,4.5,6.440000057220459,4.5,4.869999885559082,64494,0.0,0.0,4.339999961853027,5.079499995708465,6.24508333603541,12.211979916233998,-14.558520218136076,-18.664015796255118,52.500369602604884,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-20,5.420000076293945,5.480000019073486,4.46999979019165,4.599999904632568,57976,0.0,0.0,4.411999940872192,5.048499989509582,6.222750000158945,4.261105310060611,-12.607706248588514,-18.87027456702213,47.69834067847592,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-21,4.480000019073486,4.480000019073486,4.130000114440918,4.369999885559082,48264,0.0,0.0,4.378999948501587,5.012249982357025,6.1972500006357825,-0.2055278156736343,-12.63404730579001,-19.121384778041666,44.005832435953664,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-22,4.369999885559082,4.400000095367432,4.369999885559082,4.369999885559082,820,0.0,0.0,4.400999927520752,4.973499977588654,6.174583331743876,-0.7043863320200907,-11.511009402788252,-19.45205513674722,44.005832435953664,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-26,4.300000190734863,4.300000190734863,3.950000047683716,4.139999866485596,65590,0.0,0.0,4.398999929428101,4.926999974250793,6.150749997297923,-5.887703275689224,-10.716461286423716,-19.895948032105572,40.38041248810723,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-27,4.139999866485596,4.159999847412109,3.809999942779541,4.059999942779541,36770,0.0,0.0,4.389999914169311,4.877999973297119,6.1259166638056435,-7.517083777716062,-10.004101307896498,-20.371101322381893,39.1715815408591,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-28,4.28000020980835,4.28000020980835,3.8499999046325684,3.9700000286102295,38735,0.0,0.0,4.3859998941421505,4.826249974966049,6.100249995787938,-9.484721285276859,-9.121990843978104,-20.884390339765627,37.80060270933941,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-29,3.9700000286102295,4.090000152587891,3.5999999046325684,4.010000228881836,5772,0.0,0.0,4.337999939918518,4.7764999806880954,6.076166663567225,-7.5610815025240194,-9.180363080550201,-21.3895825253107,38.82539435202321,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-06-30,4.010000228881836,4.099999904632568,3.75,3.990000009536743,11674,0.0,0.0,4.287999963760376,4.731249976158142,6.051083330313364,-6.949625856859859,-9.368560414930624,-21.8115217079133,38.48397619614399,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-03,3.990000009536743,4.440000057220459,3.7699999809265137,4.079999923706055,51530,0.0,0.0,4.245999956130982,4.6862499713897705,6.024666663010915,-3.9095627447012227,-9.394505584349497,-22.215614016265782,40.99833373175701,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-04,3.9600000381469727,4.400000095367432,3.9600000381469727,4.059999942779541,5368,0.0,0.0,4.164999961853027,4.645749974250793,5.999833329518636,-2.521008884397957,-10.348168004355317,-22.568682843336255,40.60118819148423,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-05,4.289999961853027,4.440000057220459,4.059999942779541,4.400000095367432,48911,0.0,0.0,4.144999980926514,4.614249980449676,5.977333331108094,6.151993139066768,-10.169583388662273,-22.804205071925036,49.54848614125096,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-06,4.449999809265137,4.599999904632568,4.239999771118164,4.440000057220459,15551,0.0,0.0,4.151999998092651,4.579249978065491,5.954666666189829,6.936417612237704,-9.330130087227335,-23.098130680158064,50.49329362570833,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-07,4.429999828338623,4.599999904632568,4.429999828338623,4.449999809265137,5176,0.0,0.0,4.159999990463257,4.547999978065491,5.933583331108093,6.97114950641106,-8.53122228393833,-23.35154451743152,50.74164317752209,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-10,4.199999809265137,4.53000020980835,4.0,4.46999979019165,15510,0.0,0.0,4.192999982833863,4.520749974250793,5.910916662216186,6.606243942089785,-7.249903075457017,-23.518631160064032,51.26818991117052,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-11,4.460000038146973,4.46999979019165,4.139999866485596,4.460000038146973,8429,0.0,0.0,4.232999992370606,4.49524997472763,5.888833328088125,5.362628069584292,-5.833935461462622,-23.664846255938045,50.97479214738832,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-12,4.489999771118164,4.489999771118164,4.21999979019165,4.440000057220459,3105,0.0,0.0,4.279999995231629,4.472249972820282,5.8662499944369,3.738319209511382,-4.298730588787207,-23.763051744105354,50.354110679239895,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-13,4.440000057220459,4.440000057220459,4.190000057220459,4.440000057220459,6999,0.0,0.0,4.322999978065491,4.455249977111817,5.838416659832001,2.706455696243712,-2.968408051753329,-23.69078404828998,50.354110679239895,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-14,4.190000057220459,4.190000057220459,4.059999942779541,4.150000095367432,26466,0.0,0.0,4.33899998664856,4.428499984741211,5.81299999554952,-4.355839867773572,-2.021000302608815,-23.817306242358395,41.795871388834016,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-17,4.25,4.25,4.070000171661377,4.079999923706055,16230,0.0,0.0,4.33899998664856,4.39799997806549,5.786749994754791,-5.969118777125333,-1.3415186837468471,-23.998790650159197,40.02742072321559,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-18,4.079999923706055,4.21999979019165,3.950000047683716,4.03000020980835,10654,0.0,0.0,4.33600001335144,4.365749979019165,5.758666662375132,-7.0571910193923895,-0.6814399773394476,-24.188180442127997,38.76570828161408,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-19,4.03000020980835,4.289999961853027,3.9000000953674316,4.110000133514404,16691,0.0,0.0,4.307000017166137,4.340999984741211,5.731916662057241,-4.573946665116393,-0.7832289263898917,-24.26617062532127,41.92023608006833,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-20,4.21999979019165,4.21999979019165,3.9000000953674316,4.130000114440918,22371,0.0,0.0,4.276000022888184,4.3177499890327455,5.705249996980031,-3.4144038275437465,-0.9669380175000521,-24.319705686547184,42.71476020282781,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-21,4.130000114440918,4.139999866485596,3.9800000190734863,3.9800000190734863,7068,0.0,0.0,4.229000043869019,4.297249984741211,5.676749996344248,-5.887917290436531,-1.5882236573282,-24.30087660177772,38.46473392985376,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-24,4.0,4.230000019073486,4.0,4.090000152587891,22355,0.0,0.0,4.191000080108642,4.285749983787537,5.649999996026357,-2.409924256506657,-2.2108126707652516,-24.146017932713214,42.94777376932179,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-25,4.239999771118164,4.880000114440918,4.150000095367432,4.420000076293945,44663,0.0,0.0,4.18700008392334,4.284499990940094,5.625083331267039,5.564843269653769,-2.2756426006050936,-23.832239655460913,53.81775647580482,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-26,4.420000076293945,4.840000152587891,4.420000076293945,4.510000228881836,65137,0.0,0.0,4.194000101089477,4.279250001907348,5.60183333158493,7.5345760652287845,-1.9921692067505634,-23.609830057249894,56.2651189508969,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-27,4.909999847412109,4.909999847412109,4.119999885559082,4.380000114440918,71332,0.0,0.0,4.188000106811524,4.269500005245209,5.578583331902822,4.58452728587848,-1.9088862474191288,-23.466232352777144,51.98016557695344,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-28,4.199999809265137,4.440000057220459,4.199999809265137,4.389999866485596,19590,0.0,0.0,4.21200008392334,4.273500001430511,5.555999998251597,4.226015646145352,-1.4390995082855884,-23.083153297780278,52.28120715918657,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-07-31,4.25,4.389999866485596,4.099999904632568,4.25,24392,0.0,0.0,4.229000091552734,4.271249997615814,5.531833330790202,0.4965691178208328,-0.9891695893863226,-22.78780393035302,47.76628403440331,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-01,4.210000038146973,4.239999771118164,4.019999980926514,4.159999847412109,6211,0.0,0.0,4.2420000553131105,4.2707499980926515,5.504416664441426,-1.9330553237097627,-0.6731825274806755,-22.41230527329573,45.071598905035245,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-02,4.199999809265137,4.199999809265137,4.050000190734863,4.050000190734863,2172,0.0,0.0,4.236000061035156,4.275,5.475666666030884,-4.39093171908123,-0.9122792740314409,-21.927314777566696,41.95618784480731,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-03,3.990000009536743,4.340000152587891,3.930000066757202,4.21999979019165,18852,0.0,0.0,4.24500002861023,4.262999999523163,5.449166663487753,-0.5889337632528658,-0.42223717839423414,-21.76785437510148,47.94469582834327,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-04,4.059999942779541,4.650000095367432,3.9200000762939453,4.139999866485596,19696,0.0,0.0,4.26100001335144,4.262749993801117,5.4194999972979225,-2.839712426348319,-0.041052852084265845,-21.344220021654074,45.56240018130853,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-07,3.9000000953674316,4.119999885559082,3.9000000953674316,4.110000133514404,4474,0.0,0.0,4.263000011444092,4.261500000953674,5.390416665871938,-3.5890189425042665,0.03519911979541935,-20.94303158540071,44.66611590485241,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-08,4.090000152587891,4.400000095367432,3.950000047683716,3.950000047683716,70425,0.0,0.0,4.216000008583069,4.256499999761582,5.362583333253861,-6.3092969724340975,-0.9514857554512304,-20.62594210207153,40.131766617840874,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-09,4.0,4.320000171661377,3.880000114440918,4.119999885559082,32346,0.0,0.0,4.176999974250793,4.259249991178512,5.337416666746139,-1.364617884680142,-1.9310915559798074,-20.20015941953642,46.362231587730555,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-10,4.309999942779541,4.309999942779541,3.9100000858306885,4.019999980926514,24958,0.0,0.0,4.140999960899353,4.247499996423722,5.310916668176651,-2.9219990609842967,-2.507358107452358,-20.023222697599248,43.494774909548305,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-11,4.0,4.210000038146973,3.8299999237060547,4.150000095367432,27509,0.0,0.0,4.116999983787537,4.239000004529953,5.284416669607163,0.8015572433773911,-2.8780377591894974,-19.783009751858284,47.997596904288685,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-14,4.0,4.110000133514404,3.9000000953674316,4.079999923706055,45411,0.0,0.0,4.099999976158142,4.228500002622605,5.257833335796992,-0.4878061602046252,-3.038903308141517,-19.57713885996272,45.87759212833912,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-15,4.079999923706055,4.079999923706055,3.7300000190734863,4.0,23683,0.0,0.0,4.083999991416931,4.206750005483627,5.232083334525426,-2.0568068460692532,-2.9179298486168124,-19.597037422470667,43.512197979388155,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-16,4.0,4.090000152587891,3.6500000953674316,3.990000009536743,1528,0.0,0.0,4.0779999732971195,4.191500008106232,5.2078333338101706,-2.1579196747573084,-2.7078619727927142,-19.515473337169297,43.2122784372831,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-17,3.799999952316284,4.150000095367432,3.799999952316284,3.9700000286102295,31474,0.0,0.0,4.052999997138977,4.181500011682511,5.183666668335596,-2.0478650033885466,-3.073060245952953,-19.333161655142987,42.58013525529278,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-18,4.110000133514404,4.110000133514404,3.5,3.950000047683716,22674,0.0,0.0,4.034000015258789,4.171000015735626,5.155000003178914,-2.0822996345398908,-3.284584031646795,-19.08826356617824,41.91972860483563,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-21,3.950000047683716,4.119999885559082,3.690000057220459,3.8399999141693115,87958,0.0,0.0,4.00699999332428,4.163500016927719,5.128916670878728,-4.167708495961896,-3.7588572827464835,-18.823013043524572,38.39275660971564,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-22,4.099999904632568,4.099999904632568,3.799999952316284,3.9000000953674316,24613,0.0,0.0,4.001999998092652,4.159500020742416,5.1039166708787285,-2.548723207741957,-3.7865133276679916,-18.503763110492052,41.29416493007569,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-23,3.7300000190734863,3.890000104904175,3.619999885559082,3.8499999046325684,12774,0.0,0.0,3.975,4.1565000176429745,5.078500002622604,-3.1446564872309866,-4.366655043247121,-18.15496671268085,39.619640868419346,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-24,3.8499999046325684,4.0,3.740000009536743,3.809999942779541,45491,0.0,0.0,3.9539999961853027,4.151500010490418,5.051083336273829,-3.6418829930371404,-4.757316965098222,-17.809710628275475,38.28220713602753,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-25,4.110000133514404,4.110000133514404,3.7300000190734863,3.75,27018,0.0,0.0,3.9139999866485597,4.1455000102519985,5.024583337704341,-4.190086540827712,-5.584369148014217,-17.495646272910314,36.30261555982462,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-28,3.75,4.110000133514404,3.75,3.9100000858306885,14015,0.0,0.0,3.8970000028610228,4.141250014305115,5.000000003973643,0.3335920698003993,-5.897977919719395,-17.174999779721098,44.538732126897315,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-29,3.950000047683716,4.010000228881836,3.7899999618530273,3.890000104904175,34216,0.0,0.0,3.8860000133514405,4.137000018358231,4.976750006278356,0.10293596343260042,-6.0671985470862975,-16.873461332410685,43.77676092310726,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-30,3.7300000190734863,3.890000104904175,3.630000114440918,3.869999885559082,37795,0.0,0.0,3.874000000953674,4.123750013113022,4.95566667119662,-0.10325543091397489,-6.056380997033606,-16.787179471106743,42.98479690815667,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-08-31,3.869999885559082,3.869999885559082,3.5899999141693115,3.5999999046325684,27013,0.0,0.0,3.8369999885559083,4.102750009298324,4.932750004529953,-6.176702752937385,-6.4773632353940584,-16.826313810134398,34.0335630921758,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-01,3.509999990463257,3.880000114440918,3.4000000953674316,3.690000057220459,81473,0.0,0.0,3.8109999895095825,4.083750015497207,4.909333338340123,-3.1750179118917914,-6.678910926295196,-16.816607591002384,38.621805229129144,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-04,3.5,3.690000057220459,3.380000114440918,3.5299999713897705,107289,0.0,0.0,3.7799999952316283,4.06025002002716,4.884833339850108,-6.613757252836676,-6.902284918741463,-16.880480099414196,34.08317316958177,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-05,3.9000000953674316,3.9000000953674316,3.5,3.5199999809265137,23459,0.0,0.0,3.7419999837875366,4.036750018596649,4.861833337942759,-5.932656435672173,-7.3016667728060245,-16.97062120387772,33.81570328831404,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-06,3.5199999809265137,3.75,3.390000104904175,3.490000009536743,152201,0.0,0.0,3.705999994277954,4.013000017404556,4.840333336591721,-5.828385997698699,-7.650137597685758,-17.092486439574937,32.979550703540355,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-07,3.549999952316284,3.7100000381469727,3.4100000858306885,3.549999952316284,41271,0.0,0.0,3.6799999952316282,3.990750014781952,4.816166671117147,-3.532609866407392,-7.78675733632247,-17.138457048948705,36.36841762550771,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-08,3.390000104904175,3.609999895095825,3.390000104904175,3.5199999809265137,92132,0.0,0.0,3.6569999933242796,3.9750000119209288,4.7940000057220455,-3.7462404333566983,-8.000000443848423,-17.083854668827094,35.404455896533136,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-11,3.390000104904175,3.450000047683716,3.200000047683716,3.369999885559082,110752,0.0,0.0,3.602999973297119,3.957250010967255,4.770416673024496,-6.4668356776261,-8.951924611494231,-17.04603010163648,30.982564009594014,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-12,3.319999933242798,3.390000104904175,3.25,3.359999895095825,30563,0.0,0.0,3.549999952316284,3.9405000030994417,4.74316667119662,-5.352114359790027,-9.909911190864246,-16.922590407194754,30.7072151000815,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-13,3.559999942779541,3.559999942779541,3.200000047683716,3.3299999237060547,68216,0.0,0.0,3.4959999561309814,3.9209999978542327,4.720250004529953,-4.748284739929995,-10.839072735420368,-16.932365995629304,29.850141078910298,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-14,3.3499999046325684,3.9800000190734863,3.3499999046325684,3.4800000190734863,38514,0.0,0.0,3.4839999675750732,3.904749995470047,4.699583337704341,-0.1148090854998185,-10.77533845657447,-16.912847057257522,39.015559971788605,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-15,3.5899999141693115,3.6700000762939453,3.380000114440918,3.4000000953674316,67095,0.0,0.0,3.4549999713897703,3.8902499973773956,4.678666673103968,-1.591892228011077,-11.188227653262599,-16.85131108524799,36.29210385035167,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-18,3.4000000953674316,3.75,3.3299999237060547,3.440000057220459,21879,0.0,0.0,3.4459999799728394,3.87399999499321,4.659000005324682,-0.17411267519588497,-11.048012792295339,-16.84910945340868,38.59994537507833,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-19,3.5999999046325684,3.740000009536743,3.259999990463257,3.3499999046325684,58959,0.0,0.0,3.428999972343445,3.8472499907016755,4.636333336432775,-2.3038806750670946,-10.871402153982421,-17.01955593939725,35.48516189415038,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-20,3.3499999046325684,3.4100000858306885,3.3399999141693115,3.4100000858306885,9196,0.0,0.0,3.4209999799728394,3.819749987125397,4.615750002861023,-0.3215403158885227,-10.43916508924821,-17.24530174386035,39.01810072813732,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-21,3.390000104904175,3.990000009536743,3.2300000190734863,3.299999952316284,83588,0.0,0.0,3.3959999799728395,3.792749983072281,4.592083336909612,-2.8268559547318706,-10.460747607150681,-17.406769328695752,35.21111207722441,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-22,3.299999952316284,3.450000047683716,3.109999895095825,3.25,37777,0.0,0.0,3.368999981880188,3.764249986410141,4.569166670242946,-3.5322048833546096,-10.500099779687904,-17.61626882807509,33.60604240484916,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-25,3.1500000953674316,3.25,3.0999999046325684,3.25,43632,0.0,0.0,3.35699999332428,3.739249986410141,4.544333336750666,-3.187369482784023,-10.22263808183736,-17.716203691082747,33.60604240484916,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-26,3.5899999141693115,3.5899999141693115,3.0799999237060547,3.1700000762939453,65425,0.0,0.0,3.338000011444092,3.714499992132187,4.520083338022232,-5.0329519045587485,-10.135953196542548,-17.822311794864582,30.985106002312506,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-27,3.2100000381469727,3.5299999713897705,3.200000047683716,3.2899999618530273,123648,0.0,0.0,3.334000015258789,3.695499986410141,4.494666669766108,-1.319737648601849,-9.782166756345141,-17.78033260467686,38.70703311651669,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-28,3.299999952316284,3.390000104904175,3.190000057220459,3.319999933242798,12904,0.0,0.0,3.31800000667572,3.67299998998642,4.470500004291535,0.060275062177637735,-9.665123448911645,-17.839168181177513,40.49940800835912,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-09-29,3.2100000381469727,3.3399999141693115,3.2100000381469727,3.3399999141693115,9526,0.0,0.0,3.3119999885559084,3.6529999911785125,4.445833335320155,0.8454083849683711,-9.334793414893834,-17.83317736728763,41.72292326947091,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-02,3.3299999237060547,3.390000104904175,3.200000047683716,3.390000104904175,25795,0.0,0.0,3.30699999332428,3.634999990463257,4.421583334604899,2.509831017461268,-9.023383713879335,-17.789630650757136,44.78003288234786,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-03,3.509999990463257,3.509999990463257,3.259999990463257,3.3399999141693115,36575,0.0,0.0,3.305999994277954,3.6197499871253966,4.396083333094915,1.02843073049621,-8.66772550489337,-17.65965945470299,42.38552901267104,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-04,3.2799999713897705,3.490000009536743,3.2200000286102295,3.2300000190734863,20018,0.0,0.0,3.287999987602234,3.5974999904632567,4.369666665792465,-1.763989317136339,-8.603196766684855,-17.67106588184505,37.61957046292551,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-05,3.5899999141693115,3.5899999141693115,3.0899999141693115,3.2699999809265137,54958,0.0,0.0,3.2849999904632567,3.578749990463257,4.34408333102862,-0.4566212962036492,-8.208173266721413,-17.61783286012938,40.250556290646784,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-06,3.130000114440918,3.2300000190734863,3.0,3.1500000953674316,51012,0.0,0.0,3.275,3.553749990463257,4.316166665156683,-3.8167909811471232,-7.843826696061982,-17.664208401594447,35.423644849205715,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-09,3.1500000953674316,3.450000047683716,3.1500000953674316,3.25,40540,0.0,0.0,3.275,3.5329999923706055,4.290583330392837,-0.7633587786259515,-7.302575514513101,-17.656884383431123,41.69819874340697,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-10,3.2799999713897705,3.6500000953674316,3.2799999713897705,3.4200000762939453,31854,0.0,0.0,3.3,3.518499994277954,4.268249998490016,3.636365948301379,-6.210032531854345,-17.565747190940126,50.50304920713384,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-11,3.380000114440918,3.619999885559082,3.299999952316284,3.299999952316284,14135,0.0,0.0,3.3009999990463257,3.5012499928474425,4.247083330154419,-0.030295265990015818,-5.719385768231324,-17.561071430163324,45.3021752421823,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-12,3.3499999046325684,3.390000104904175,3.259999990463257,3.3399999141693115,11740,0.0,0.0,3.302999997138977,3.48549998998642,4.226416661341985,1.1201912522671358,-5.235977431408742,-17.53061117074782,47.25213730499706,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-13,3.25,3.3399999141693115,3.1500000953674316,3.200000047683716,17315,0.0,0.0,3.2890000104904176,3.4667499899864196,4.2037499944369,-2.7059885230414182,-5.127280017579183,-17.53196563605831,41.65488624666852,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-16,3.1600000858306885,3.1600000858306885,2.869999885559082,3.049999952316284,85506,0.0,0.0,3.2549999952316284,3.446999990940094,4.179166660706202,-6.298004399866559,-5.5700608126808175,-17.519441774125983,36.64612850101212,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-17,3.049999952316284,3.0899999141693115,2.890000104904175,3.0899999141693115,20274,0.0,0.0,3.2299999952316285,3.426749986410141,4.154749993483225,-4.334367841145379,-5.741591652696779,-17.52211344160204,38.760815984951215,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-18,3.0999999046325684,3.0999999046325684,2.9700000286102295,3.0399999618530273,34991,0.0,0.0,3.2109999895095824,3.4064999878406526,4.129749993483226,-5.325444665687215,-5.739028299688787,-17.513166820845495,37.09405971089776,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-19,3.359999895095825,3.359999895095825,2.9600000381469727,3.119999885559082,7594,0.0,0.0,3.1959999799728394,3.389249986410141,4.105749992529551,-2.3779754346057036,-5.701851654855066,-17.451135783306054,41.43349448817816,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-20,3.0,3.059999942779541,2.7100000381469727,2.950000047683716,24954,0.0,0.0,3.175999975204468,3.3692499876022337,4.081999991337458,-7.115866791094744,-5.735698244679507,-17.460803656241396,35.784399714247996,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-23,3.4800000190734863,3.4800000190734863,2.9800000190734863,3.119999885559082,26890,0.0,0.0,3.162999963760376,3.349499982595444,4.058999989430109,-1.359471346631721,-5.567995814424624,-17.479675010649125,44.00595238509876,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-24,3.0999999046325684,3.0999999046325684,2.8399999141693115,2.9100000858306885,41506,0.0,0.0,3.1119999647140504,3.3249999821186065,4.035916658242543,-6.49099875237058,-6.406015595489954,-17.614751153793858,37.60160682150804,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-25,3.0899999141693115,3.0999999046325684,2.9100000858306885,2.9100000858306885,17985,0.0,0.0,3.0729999780654906,3.3009999871253966,4.0129999935626985,-5.304259466263113,-6.9069981808286744,-17.742337592310733,37.60160682150804,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-26,2.759999990463257,3.4000000953674316,2.759999990463257,3.049999952316284,16862,0.0,0.0,3.043999981880188,3.2872499883174897,3.989749991893768,0.19710809697147275,-7.399802488456437,-17.607619650444086,43.912718054791355,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-27,3.4000000953674316,3.4000000953674316,2.990000009536743,3.0199999809265137,44591,0.0,0.0,3.025999975204468,3.270499986410141,3.9674166599909464,-0.1982813723436616,-7.475921486672998,-17.56600663118644,42.91114995448597,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-30,3.200000047683716,3.200000047683716,2.8499999046325684,3.0399999618530273,28871,0.0,0.0,3.024999976158142,3.2582499861717222,3.9464166601498922,0.4958672996069167,-7.158751200905766,-17.43776020730746,43.83092341275062,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-10-31,3.0199999809265137,3.5199999809265137,2.930000066757202,3.0,8324,0.0,0.0,3.015999984741211,3.2452499866485596,3.92574999332428,-0.5305034755357931,-7.064170798875804,-17.334267536977837,42.36094846746865,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-01,3.109999895095825,3.200000047683716,2.8399999141693115,3.0799999237060547,4951,0.0,0.0,3.0199999809265137,3.2349999845027924,3.906749991575877,1.9867530847180164,-6.646058874999452,-17.194599309440807,46.24398150807313,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-02,3.2899999618530273,3.2899999618530273,2.9000000953674316,2.9200000762939453,7896,0.0,0.0,3.0,3.219249987602234,3.888416659832001,-2.6666641235351562,-6.810592170430849,-17.209232722983923,40.3842117785234,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-03,2.9200000762939453,3.069999933242798,2.9200000762939453,3.0,10035,0.0,0.0,3.0049999952316284,3.206249988079071,3.8699166615804037,-0.16638919266430857,-6.276802919164005,-17.14937895407554,44.19203029968453,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-06,3.0,3.1600000858306885,2.809999942779541,2.990000009536743,63606,0.0,0.0,2.9920000076293944,3.1967499911785127,3.850666660070419,-0.06684485586736032,-6.4049420228084575,-16.981907981615528,43.815295797358836,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-07,2.990000009536743,2.990000009536743,2.9100000858306885,2.990000009536743,23413,0.0,0.0,3.0,3.1874999940395354,3.831249992052714,-0.33333301544189453,-5.882352765181207,-16.802610097188385,43.815295797358836,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-08,3.200000047683716,3.200000047683716,2.690000057220459,2.940000057220459,44502,0.0,0.0,3.002999997138977,3.1777499973773957,3.8132499933242796,-2.0979000991854666,-5.499173955869409,-16.665573908330977,41.751336201063864,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-09,3.059999942779541,3.059999942779541,2.799999952316284,2.950000047683716,16191,0.0,0.0,2.9930000066757203,3.1644999980926514,3.7956666608651477,-1.436684226398111,-5.419497282992566,-16.6286114974236,42.336384860865486,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-10,2.9100000858306885,3.0299999713897705,2.8499999046325684,2.950000047683716,4733,0.0,0.0,2.9860000133514406,3.1532499969005583,3.780249993006388,-1.2056251006951262,-5.304050859066476,-16.586204543768392,42.336384860865486,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-13,2.950000047683716,3.0899999141693115,2.759999990463257,3.0399999618530273,19250,0.0,0.0,2.9860000133514406,3.1432499945163728,3.7676666577657065,1.8084376510426745,-5.002783152446231,-16.573033656316717,47.80807177995919,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-14,3.0399999618530273,3.0799999237060547,3.0,3.0,6931,0.0,0.0,2.9860000133514406,3.1344999969005585,3.7554166595141094,0.4688542058258741,-4.737597182834804,-16.53389540786368,45.731088148051015,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-15,3.0399999618530273,3.0399999618530273,2.9200000762939453,3.009999990463257,3411,0.0,0.0,2.9790000200271605,3.1244999945163725,3.741166661183039,1.0406166575256932,-4.656744270909603,-16.483271730847274,46.358506759375395,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-16,2.9800000190734863,2.9800000190734863,2.880000114440918,2.9600000381469727,16760,0.0,0.0,2.9830000162124635,3.11599999666214,3.7260833283265433,-0.7710351304219585,-4.268292060081709,-16.373314225863105,43.64167714000697,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-17,3.0,3.1500000953674316,2.950000047683716,3.0799999237060547,8730,0.0,0.0,2.991000008583069,3.111749994754791,3.716499994198481,2.975590600721788,-3.8804526833858732,-16.27203014631279,51.05536036129815,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-20,3.0799999237060547,3.0999999046325684,2.9200000762939453,2.950000047683716,5636,0.0,0.0,2.987000012397766,3.1042499959468843,3.7049166599909467,-1.238699851371915,-3.777079284922532,-16.21269030233814,44.26241854604253,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-21,2.950000047683716,3.0999999046325684,2.759999990463257,2.9600000381469727,32548,0.0,0.0,2.984000015258789,3.0989999949932097,3.6947499950726828,-0.8042887730928788,-3.7108738276933346,-16.12423035046932,44.87005723971786,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-22,3.1500000953674316,3.1500000953674316,2.9000000953674316,3.049999952316284,9123,0.0,0.0,2.9950000047683716,3.0929999947547913,3.6878333270549772,1.8363922357377827,-3.168444557148762,-16.12961540144242,50.138583030515875,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-23,3.0999999046325684,3.1500000953674316,2.9800000190734863,3.0799999237060547,47568,0.0,0.0,3.0079999923706056,3.086999994516373,3.6743333280086516,2.3936147446166034,-2.55911895970521,-15.98475916747028,51.79237446523306,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-24,2.9800000190734863,3.1500000953674316,2.9800000190734863,3.0799999237060547,5253,0.0,0.0,3.0209999799728395,3.080499994754791,3.6654166599114735,1.952993847214312,-1.9315051090168165,-15.95771284486957,51.79237446523306,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-27,3.0,3.0,2.930000066757202,3.0,5516,0.0,0.0,3.0169999837875365,3.070749992132187,3.6557499945163725,-0.5634731149781043,-1.7503869895747766,-16.002188422668016,46.97388713789198,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-28,3.0,3.0,2.799999952316284,2.940000057220459,41565,0.0,0.0,3.0109999895095827,3.0607499957084654,3.645666660865148,-2.3580183505974652,-1.6254188113579389,-16.04416200294836,43.69081101754471,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-29,2.940000057220459,2.940000057220459,2.740000009536743,2.869999885559082,49063,0.0,0.0,2.996999979019165,3.0517499923706053,3.6361666580041248,-4.237574052357738,-1.7940530347608958,-16.072328927692855,40.16390911659065,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-11-30,2.799999952316284,3.119999885559082,2.7899999618530273,3.119999885559082,25665,0.0,0.0,3.012999963760376,3.04799998998642,3.624749992291133,3.551275243467463,-1.1482948274615854,-15.911442265847436,54.34020621813735,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-01,3.119999885559082,3.140000104904175,2.950000047683716,2.950000047683716,6394,0.0,0.0,2.999999976158142,3.042999988794327,3.611916661262512,-1.6666642957263365,-1.4130796186174754,-15.751101861506564,46.30620386475159,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-04,2.950000047683716,3.130000114440918,2.9000000953674316,2.950000047683716,34815,0.0,0.0,2.999999976158142,3.0354999899864197,3.5989999949932097,-1.6666642957263365,-1.1694947766557666,-15.657127140614325,46.306203864751595,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-05,3.0,3.119999885559082,2.7699999809265137,2.950000047683716,45183,0.0,0.0,2.9989999771118163,3.023749989271164,3.5829999963442485,-1.6338756186083678,-0.8185204546396202,-15.608428904373145,46.306203864751595,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-06,3.0799999237060547,3.180000066757202,2.990000009536743,2.990000009536743,51398,0.0,0.0,2.9929999828338625,3.0159999907016752,3.5695833305517835,-0.10023298744822756,-0.7625997327162386,-15.508346173404384,48.54198270232613,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-07,3.0,3.0,2.7300000190734863,2.8499999046325684,27357,0.0,0.0,2.969999980926514,3.0037499904632567,3.556916664044062,-4.040406635171443,-1.123595826679895,-15.551859259808426,41.95689530910503,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-08,2.9000000953674316,3.109999895095825,2.9000000953674316,3.0,7161,0.0,0.0,2.9619999885559083,2.9987499892711638,3.5454999983310698,1.2829173393284925,-1.2255106576653105,-15.420956404379382,49.8126224806849,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-11,3.0,3.0899999141693115,2.930000066757202,3.0,28787,0.0,0.0,2.9619999885559083,2.9974999904632567,3.53599999944369,1.2829173393284925,-1.1843203342883721,-15.229072654557527,49.8126224806849,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-12,2.819999933242798,3.0899999141693115,2.819999933242798,3.0899999141693115,64368,0.0,0.0,2.9769999742507935,2.9974999904632567,3.527916665871938,3.795765565868239,-0.6839037957526359,-15.034841399168558,54.132402916387996,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-13,3.069999933242798,3.0899999141693115,2.940000057220459,2.940000057220459,52547,0.0,0.0,2.983999991416931,2.9949999928474424,3.5193333327770233,-1.4745286301284144,-0.3672788466371024,-14.898655238088566,46.888582036645566,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-14,2.940000057220459,2.9600000381469727,2.809999942779541,2.930000066757202,14966,0.0,0.0,2.9650000095367433,2.9902499973773957,3.5103333314259846,-1.1804365149061014,-0.8444105965319961,-14.815782005446135,46.44239349285886,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-15,2.9800000190734863,3.0,2.880000114440918,2.950000047683716,26005,0.0,0.0,2.9650000095367433,2.9902499973773957,3.5016666650772095,-0.5059009040398301,-0.8444105965319961,-14.604950059932028,47.51805570177223,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-18,3.0199999809265137,3.0199999809265137,2.819999933242798,2.9000000953674316,9266,0.0,0.0,2.960000014305115,2.9847500026226044,3.491833333174388,-2.0270242786390216,-0.8292147850152446,-14.521979778765656,45.08042748462543,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-19,2.9000000953674316,2.9000000953674316,2.75,2.8399999141693115,42711,0.0,0.0,2.9490000009536743,2.9829999983310698,3.4816666662693025,-3.696171134252742,-1.1397920682674418,-14.32264245079404,42.27765798685326,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-20,2.8399999141693115,2.930000066757202,2.700000047683716,2.7200000286102295,95369,0.0,0.0,2.922000002861023,2.9782499969005585,3.467666665712992,-6.913072349521185,-1.8886928262595242,-14.113717262723233,37.284851561170534,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-21,2.7899999618530273,2.819999933242798,2.700000047683716,2.7899999618530273,17016,0.0,0.0,2.916000008583069,2.971749997138977,3.4539166649182635,-4.320989244141565,-1.875998607203871,-13.95999714401612,41.61624197276615,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-22,3.0,3.0899999141693115,2.7200000286102295,2.8399999141693115,30449,0.0,0.0,2.9,2.967249995470047,3.4404999991257985,-2.0689684769202894,-2.2664081412996677,-13.755268239383817,44.56149772486018,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-27,2.8399999141693115,2.9200000762939453,2.6500000953674316,2.7200000286102295,35846,0.0,0.0,2.872000002861023,2.959249997138977,3.4259166677792865,-5.292478206802728,-2.948382000922801,-13.621658548478575,39.4215302546573,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-28,2.7100000381469727,2.7699999809265137,2.5999999046325684,2.7200000286102295,32834,0.0,0.0,2.835000014305115,2.9522499978542327,3.4114166676998137,-4.056436864712783,-3.971546570728699,-13.459706467201476,39.4215302546573,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2023-12-29,2.7200000286102295,2.7200000286102295,2.5799999237060547,2.630000114440918,46509,0.0,0.0,2.8040000200271606,2.941000002622604,3.396333334843318,-6.205417415958408,-4.658278900825411,-13.406614938215991,35.82700359727207,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-02,2.630000114440918,2.630000114440918,2.440000057220459,2.5899999141693115,28289,0.0,0.0,2.7700000047683715,2.9327499985694887,3.3809166669845583,-6.498198205386345,-5.549398819555093,-13.255773879064275,34.32879745165717,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-03,2.5999999046325684,2.5999999046325684,2.549999952316284,2.5999999046325684,2247,0.0,0.0,2.734999990463257,2.9227499961853027,3.3679999987284344,-4.936017780673634,-6.423744965087408,-13.220011956984346,35.059929708044024,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-04,2.5999999046325684,2.890000104904175,2.430000066757202,2.75,6206,0.0,0.0,2.719999980926514,2.9167499959468843,3.356916666030884,1.1029418854358684,-6.745522080869951,-13.112231070199284,44.95879746109736,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-05,2.4600000381469727,2.6600000858306885,2.4600000381469727,2.630000114440918,6469,0.0,0.0,2.6990000009536743,2.9077499985694883,3.3452499985694883,-2.5564982026074725,-7.179090283501393,-13.078245278741074,39.73995572553033,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-08,2.630000114440918,2.880000114440918,2.4700000286102295,2.7200000286102295,59556,0.0,0.0,2.6990000009536743,2.902249997854233,3.333666664361954,0.7780669747734328,-7.00318708074186,-12.941205883591,44.90547330272843,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-09,2.690000057220459,2.700000047683716,2.4600000381469727,2.5899999141693115,192801,0.0,0.0,2.678999996185303,2.8932499945163728,3.3208333293596906,-3.3221381912176486,-7.405167155867683,-12.875784251592135,39.62213314248413,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-10,2.5,2.6700000762939453,2.4800000190734863,2.569999933242798,29518,0.0,0.0,2.651999998092651,2.8837499916553497,3.3090833286444346,-3.092008480725065,-8.036410723305034,-12.853509408701488,38.864544582379814,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-11,2.549999952316284,2.609999895095825,2.4600000381469727,2.559999942779541,20902,0.0,0.0,2.6359999895095827,2.8717499911785125,3.2963333268960318,-2.883158081657701,-8.209280139047982,-12.880473350591796,38.46848969348473,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-12,2.559999942779541,2.640000104904175,2.4600000381469727,2.5399999618530273,8434,0.0,0.0,2.6179999828338625,2.860249990224838,3.2806666592756906,-2.979374388551514,-8.469539663277228,-12.814976732310637,37.642276073083046,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-15,2.490000009536743,2.559999942779541,2.490000009536743,2.559999942779541,4899,0.0,0.0,2.6109999656677245,2.8489999890327455,3.264416656891505,-1.9532755097199324,-8.353809206079484,-12.725601892202516,39.0519913882113,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-16,2.5,2.559999942779541,2.5,2.559999942779541,5588,0.0,0.0,2.6079999685287474,2.8389999866485596,3.2492499887943267,-1.8404918070717864,-8.136668517300974,-12.625990722800474,39.05199138821129,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-17,2.4800000190734863,2.549999952316284,2.4200000762939453,2.4600000381469727,10703,0.0,0.0,2.593999981880188,2.8234999895095827,3.233166656891505,-5.165765021944574,-8.128209969260771,-12.67075628497889,34.525879511479815,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-18,2.4600000381469727,2.5999999046325684,2.3499999046325684,2.569999933242798,4972,0.0,0.0,2.5759999752044678,2.8139999866485597,3.219166656335195,-0.2329208858472009,-8.457711889599084,-12.58607313446426,42.43003434008655,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-19,2.569999933242798,2.569999933242798,2.5,2.509999990463257,3361,0.0,0.0,2.563999962806702,2.8027499854564666,3.2054166575272878,-2.106083195271716,-8.518420261837269,-12.562069618164553,39.62041167416909,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-22,2.4800000190734863,3.450000047683716,2.4000000953674316,2.690000057220459,22665,0.0,0.0,2.5609999656677247,2.793749988079071,3.1940833230813346,5.037098527219244,-8.331097034612636,-12.533590846216924,50.261253025060235,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-23,2.890000104904175,2.890000104904175,2.690000057220459,2.7799999713897705,13956,0.0,0.0,2.5799999713897703,2.786249989271164,3.1820833245913187,7.751938070459204,-7.4024232813131405,-12.439439667124132,54.57209988577924,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-24,2.7699999809265137,2.990000009536743,2.5,2.7799999713897705,50911,0.0,0.0,2.6009999752044677,2.7787499904632567,3.170749992132187,6.881968392607594,-6.396761704681303,-12.363005681357041,54.57209988577924,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-25,2.7799999713897705,2.869999885559082,2.640000104904175,2.809999942779541,19748,0.0,0.0,2.6259999752044676,2.7739999890327454,3.159916657209396,7.006853363003048,-5.335256467678764,-12.212874896436787,56.04483873994464,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-26,2.990000009536743,2.990000009536743,2.6600000858306885,2.700000047683716,11407,0.0,0.0,2.6419999837875365,2.767999988794327,3.1494999905427297,2.195309017868772,-4.552023320696361,-12.113033906777744,49.68450163698377,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-29,2.700000047683716,2.700000047683716,2.5999999046325684,2.6700000762939453,14487,0.0,0.0,2.652999997138977,2.7629999935626985,3.1374166587988537,0.640787002386028,-3.9811797567861755,-11.933915891792928,48.08185071054053,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-30,2.5999999046325684,2.6700000762939453,2.4000000953674316,2.5199999809265137,17273,0.0,0.0,2.6490000009536745,2.747999995946884,3.1249166587988535,-4.869762928679469,-3.6026199104522565,-12.061654885760937,40.966417232088936,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-01-31,2.680000066757202,2.680000066757202,2.4600000381469727,2.5,4621,0.0,0.0,2.652999997138977,2.736749994754791,3.111166658004125,-5.767056061212735,-3.0601990600649627,-12.034606448551024,40.11402562582347,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-01,2.5,2.700000047683716,2.319999933242798,2.5899999141693115,63185,0.0,0.0,2.6549999952316283,2.727749991416931,3.0987499912579852,-2.4482139803787852,-2.66703313772215,-11.972569613156855,45.599466479712156,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-02,2.5899999141693115,2.759999990463257,2.430000066757202,2.759999990463257,33544,0.0,0.0,2.6799999952316282,2.7229999899864197,3.0884166578451793,2.9850744542525387,-1.57914046687183,-11.831844868811018,54.14376669152004,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-05,2.759999990463257,2.759999990463257,2.4000000953674316,2.5,92579,0.0,0.0,2.6609999895095826,2.710749989748001,3.0759999910990397,-6.0503566382672025,-1.8352854533458276,-11.874187334458881,43.0159134555171,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-06,2.5,2.509999990463257,2.4200000762939453,2.5,25344,0.0,0.0,2.6329999923706056,2.701999992132187,3.063749990860621,-5.05127203782708,-2.5536639512397796,-11.80742553431447,43.0159134555171,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-07,2.4700000286102295,2.4700000286102295,2.4200000762939453,2.450000047683716,44896,0.0,0.0,2.6,2.6882499933242796,3.051249990860621,-5.769228935241703,-3.282804558483414,-11.89676357635827,41.1305583825203,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-08,2.490000009536743,2.549999952316284,2.450000047683716,2.549999952316284,20505,0.0,0.0,2.5740000009536743,2.676999992132187,3.0404999911785127,-0.9324028216199709,-3.8475902682567753,-11.955270518038427,46.20854951742949,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-09,2.5,2.569999933242798,2.450000047683716,2.450000047683716,12832,0.0,0.0,2.5490000009536744,2.660999995470047,3.028416657447815,-3.8838741950929414,-4.208943807103944,-12.132302240320078,42.280914880798,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-12,2.4700000286102295,2.4700000286102295,2.359999895095825,2.430000066757202,18485,0.0,0.0,2.525,2.6482499957084658,3.01658332546552,-3.7623735937741687,-4.654016649039726,-12.210281965283125,41.52078298076665,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-13,2.3399999141693115,2.630000114440918,2.3399999141693115,2.440000057220459,34624,0.0,0.0,2.5170000076293944,2.635999995470047,3.0051666597525277,-3.0591954777726373,-4.514415327964847,-12.284399039382441,42.08146526830303,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-14,2.440000057220459,2.509999990463257,2.299999952316284,2.4700000286102295,25364,0.0,0.0,2.5140000104904177,2.62399999499321,2.99449999332428,-1.7501981581776083,-4.192072588135694,-12.3726832244794,43.82162998870385,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-15,2.4600000381469727,2.5899999141693115,2.390000104904175,2.4800000190734863,16237,0.0,0.0,2.503000020980835,2.613499993085861,2.9825833261013033,-0.9188973917121969,-4.228045624540237,-12.374619337052724,44.42107092289124,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-16,2.390000104904175,2.4700000286102295,2.200000047683716,2.4000000953674316,45076,0.0,0.0,2.4670000314712524,2.6024999976158143,2.9701666593551637,-2.715846584884871,-5.2065308844839695,-12.378654261076765,40.68128616265116,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-19,2.4000000953674316,2.450000047683716,2.259999990463257,2.4200000762939453,48483,0.0,0.0,2.459000039100647,2.594999998807907,2.9580833276112872,-1.5860090356470797,-5.240846233901197,-12.274276570044337,41.99602659725138,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-20,2.4200000762939453,2.4200000762939453,2.25,2.3399999141693115,11685,0.0,0.0,2.4430000305175783,2.583749997615814,2.94758332769076,-4.21613242167848,-5.44750719799185,-12.343445108301175,38.335870617992036,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-21,2.380000114440918,2.380000114440918,2.190000057220459,2.2899999618530273,25189,0.0,0.0,2.4270000219345094,2.569999998807907,2.935916660229365,-5.644831431533413,-5.564201437343512,-12.463455328220084,36.21163386624798,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-22,2.200000047683716,3.009999990463257,2.200000047683716,2.5999999046325684,183826,0.0,0.0,2.432000017166138,2.5669999957084655,2.928166659673055,6.9078900608804545,-5.259056438177715,-12.33422499267564,53.438354609317365,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-23,3.0,3.0,2.4000000953674316,2.4100000858306885,176940,0.0,0.0,2.428000020980835,2.559249997138977,2.9189166605472563,-0.7413482287728691,-5.1284546763648935,-12.321923002106088,45.35387941621347,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-26,2.4000000953674316,2.5399999618530273,2.259999990463257,2.380000114440918,130874,0.0,0.0,2.4230000257492064,2.552999997138977,2.909666661421458,-1.7746558337320928,-5.092047455364483,-12.257990546183011,44.216423168995796,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-27,2.5,2.799999952316284,2.4800000190734863,2.630000114440918,120320,0.0,0.0,2.4420000314712524,2.5540000021457674,2.90199999610583,7.698610997003122,-4.385276843399261,-11.991729649450061,54.46511346595035,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-28,2.7899999618530273,2.7899999618530273,2.5799999237060547,2.700000047683716,28795,0.0,0.0,2.465000033378601,2.5565000057220457,2.8951666633288067,9.533469011074084,-3.57911097745536,-11.697656715118727,56.855299846361795,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-02-29,2.700000047683716,2.75,2.6700000762939453,2.6700000762939453,4485,0.0,0.0,2.484000039100647,2.5545000076293944,2.8893333315849303,7.487924084761328,-2.759834344027741,-11.588601436022774,55.51046101396731,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-01,2.6500000953674316,3.0,2.6500000953674316,2.8399999141693115,115305,0.0,0.0,2.528000020980835,2.5597500026226045,2.8849999984105428,12.34176782433033,-1.2403547850079137,-11.273830016191713,61.12237903241148,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-04,2.990000009536743,2.990000009536743,2.759999990463257,2.869999885559082,49796,0.0,0.0,2.5730000019073485,2.563499999046326,2.881166664759318,11.542941447010085,0.37058719970964654,-11.025626167291817,62.03254770888813,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-05,2.759999990463257,2.759999990463257,2.6500000953674316,2.700000047683716,10451,0.0,0.0,2.609000015258789,2.566250002384186,2.874666664997737,3.4879276309969884,1.665855346707683,-10.72878001365747,54.2779700302858,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-06,2.700000047683716,2.75,2.5,2.75,33682,0.0,0.0,2.655000019073486,2.570750004053116,2.8692499975363415,3.578153681507917,3.2772542988442788,-10.403415308513729,56.01939781832744,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-07,2.7100000381469727,2.7799999713897705,2.630000114440918,2.7799999713897705,9524,0.0,0.0,2.6730000257492064,2.5762500047683714,2.8637499968210856,4.002990819671746,3.7554593227272477,-10.039283889021542,57.075773459416446,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-08,2.819999933242798,3.0,2.759999990463257,2.859999895095825,105402,0.0,0.0,2.7180000066757204,2.5842500030994415,2.8596666634082792,5.224425609688622,5.175582989875775,-9.631075671616347,59.84554744436205,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-11,2.869999885559082,2.990000009536743,2.819999933242798,2.930000066757202,13728,0.0,0.0,2.7730000019073486,2.593500006198883,2.8556666632493335,5.661740524409101,6.921148844396832,-9.180576305504196,62.14717159137073,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-12,2.930000066757202,3.5,2.930000066757202,2.9600000381469727,49786,0.0,0.0,2.805999994277954,2.603500008583069,2.852833330631256,5.488241061406209,7.77799059063933,-8.739848885354142,63.122757577021495,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-13,2.950000047683716,3.0,2.819999933242798,2.9600000381469727,28601,0.0,0.0,2.83199999332428,2.616000008583069,2.850416664282481,4.51977560467586,8.25688012356717,-8.223943489974664,63.122757577021495,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-14,3.0,3.0,2.940000057220459,3.0,16367,0.0,0.0,2.8649999856948853,2.6267500102519987,2.8483333309491474,4.712042407650182,9.07014274342879,-7.779402722619923,64.5361451267533,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-15,3.0,3.299999952316284,2.9000000953674316,3.1600000858306885,53540,0.0,0.0,2.8970000028610228,2.643000012636185,2.848249997695287,9.07835977597279,9.61029091980567,-7.206178714129161,69.56154624301621,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-18,3.240000009536743,3.4000000953674316,3.240000009536743,3.390000104904175,38784,0.0,0.0,2.949000024795532,2.6605000138282775,2.8490833322207134,14.95422436082276,10.843826704293937,-6.619087488937887,75.03755621642159,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-19,3.240000009536743,3.5999999046325684,3.240000009536743,3.3399999141693115,23998,0.0,0.0,3.013000011444092,2.674500012397766,2.849249998728434,10.852967191609565,12.656571227414235,-6.133192468497171,72.0048397851931,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-20,3.0,3.5899999141693115,3.0,3.3499999046325684,45543,0.0,0.0,3.0730000019073485,2.6887500107288362,2.8493333319822947,9.01398966981099,14.29102704398889,-5.635820823453459,72.24643289309483,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-21,3.180000066757202,3.2799999713897705,3.0,3.2100000381469727,12132,0.0,0.0,3.116000008583069,2.6987500131130218,2.8478333314259845,3.016689002085338,15.460861266981423,-5.234973432883898,63.92861177598788,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-22,3.009999990463257,3.2200000286102295,2.9000000953674316,3.190000057220459,15134,0.0,0.0,3.1490000247955323,2.7110000133514403,2.8465833326180774,1.3020016545598103,16.15640019501955,-4.763019501766618,62.81598379805561,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-25,3.1500000953674316,3.9800000190734863,3.1500000953674316,3.2200000286102295,44572,0.0,0.0,3.178000020980835,2.7247500121593475,2.8464999993642173,1.321586134427782,16.63455387829467,-4.277182056281866,63.83280700319701,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-26,3.2200000286102295,3.2200000286102295,2.9800000190734863,3.0199999809265137,15241,0.0,0.0,3.184000015258789,2.7372500121593477,2.8444166660308836,-5.1507548224350685,16.32112525764541,-3.7676144691233615,53.35726191597186,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-27,3.0399999618530273,3.4700000286102295,3.0199999809265137,3.240000009536743,66988,0.0,0.0,3.212000012397766,2.7557500123977663,2.8451666653156282,0.8717309162796354,16.556291316243836,-3.1427562401847036,60.94901393794937,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-03-28,3.240000009536743,3.240000009536743,3.0,3.0799999237060547,26919,0.0,0.0,3.2200000047683717,2.768000012636185,2.8437499980131786,-4.347828597981254,16.329479409998687,-2.663735751381715,54.0577609765625,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-02,3.119999885559082,3.390000104904175,3.119999885559082,3.319999933242798,44651,0.0,0.0,3.2359999895095823,2.7820000112056733,2.842916663487752,2.5957955502325496,16.31919397826145,-2.142751951347912,61.1529680909477,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-03,3.2899999618530273,3.299999952316284,2.940000057220459,3.0899999141693115,39288,0.0,0.0,3.205999970436096,2.796750009059906,2.8411666631698607,-3.61821763370153,14.633054797548912,-1.563324485174673,52.745927399542204,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-04,3.0799999237060547,3.0899999141693115,2.9800000190734863,3.0899999141693115,32235,0.0,0.0,3.1809999704360963,2.8115000069141387,2.8390833298365274,-2.8607374131571963,13.142449319340935,-0.9715573555911433,52.745927399542204,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-05,2.509999990463257,3.2899999618530273,2.5,3.0,77343,0.0,0.0,3.1459999799728395,2.825250005722046,2.8374166627724966,-4.64081312467459,11.35297667821152,-0.4287934588557159,49.64840470341917,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-08,3.0,3.1500000953674316,2.9200000762939453,3.0199999809265137,7644,0.0,0.0,3.1269999742507935,2.8370000064373015,2.837166663010915,-3.421809856263789,10.222064404493015,-0.005874049479930927,50.34623515535247,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-09,2.950000047683716,3.0,2.8399999141693115,3.0,18485,0.0,0.0,3.1079999685287474,2.850750005245209,2.8364166637261707,-3.4749024975013745,9.023939763578499,0.5053327214700724,49.60585578023021,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-10,3.180000066757202,3.180000066757202,2.880000114440918,2.9600000381469727,10935,0.0,0.0,3.081999969482422,2.864000004529953,2.835749997695287,-3.9584663382049787,7.6117306078093945,0.9962093575817973,48.08288181244235,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-11,3.069999933242798,3.069999933242798,2.9000000953674316,2.9600000381469727,15310,0.0,0.0,3.0759999752044678,2.877000004053116,2.8344166656335195,-3.771129323555485,6.916926342405315,1.5023669221221785,48.08288181244235,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-12,3.0,3.0,2.8499999046325684,2.8499999046325684,2252,0.0,0.0,3.03699996471405,2.8865000009536743,2.8335833311080934,-6.157394213176716,5.213925643881934,1.8674823946288361,43.79460196485393,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-15,2.8499999046325684,2.950000047683716,2.8499999046325684,2.8499999046325684,2337,0.0,0.0,3.0139999628067016,2.8957499980926515,2.831333331267039,-5.441276051689557,4.083569534384457,2.2751353969610384,43.79460196485393,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-16,2.8499999046325684,2.8499999046325684,2.609999895095825,2.8399999141693115,10887,0.0,0.0,2.965999960899353,2.9067499935626984,2.830749996503194,-4.24814728223515,2.038357872808804,2.684800747271447,43.38663561307991,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-17,3.190000057220459,3.190000057220459,2.680000066757202,2.8399999141693115,100620,0.0,0.0,2.940999960899353,2.9172499895095827,2.8301666617393493,-3.434207686937743,0.8141219119093395,3.0769681852133117,43.38663561307991,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-18,2.8399999141693115,2.8399999141693115,2.509999990463257,2.630000114440918,41374,0.0,0.0,2.8949999809265137,2.9244999945163728,2.826666663090388,-9.153708747203009,-1.0087199058017966,3.4610848425623697,35.36344682708011,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-19,2.619999885559082,2.619999885559082,2.359999895095825,2.5999999046325684,64981,0.0,0.0,2.8549999713897707,2.932249993085861,2.823166662454605,-8.93170120184177,-2.6344964405573625,3.8638643648623137,34.385190716801844,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-22,2.5999999046325684,2.869999885559082,2.450000047683716,2.5799999237060547,61959,0.0,0.0,2.8109999656677247,2.9317499935626983,2.8193333288033804,-8.21771770839557,-4.11870139541594,3.9873491938972423,33.71558575543568,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-23,3.0199999809265137,3.0199999809265137,2.390000104904175,2.5399999618530273,28938,0.0,0.0,2.7649999618530274,2.9349999904632567,2.8154999951521558,-8.137432300332158,-5.792164537056664,4.244361410650361,32.35837105442312,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-24,2.5,2.5399999618530273,2.369999885559082,2.4000000953674316,61436,0.0,0.0,2.7089999675750733,2.9354999899864196,2.8098333299160005,-11.406418453531359,-7.715892460704595,4.472388405833873,28.095456168944622,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-25,1.25,1.5850000381469727,1.2000000476837158,1.3049999475479126,1124739,0.0,0.0,2.5434999585151674,2.9023749858140944,2.7963749955097836,-48.69274744121721,-12.364874595908399,3.790621446498336,13.31750674634334,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-26,1.399999976158142,1.399999976158142,1.2200000286102295,1.3450000286102295,238647,0.0,0.0,2.3929999709129333,2.8684999853372575,2.782583329081535,-43.794398455545746,-16.5766085708527,3.0876579816239094,15.074807141938123,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-29,1.3450000286102295,1.3949999809265137,1.2050000429153442,1.3250000476837158,66073,0.0,0.0,2.2404999852180483,2.834874984622002,2.7687083293994266,-40.86141234431809,-20.966533008622484,2.389802295893254,14.912025789712317,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-04-30,1.3300000429153442,1.350000023841858,1.2999999523162842,1.340000033378601,43838,0.0,0.0,2.090499997138977,2.797374987602234,2.754958329598109,-35.90050058777793,-25.269225384372003,1.5396478976984185,15.647717181106401,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-02,1.340000033378601,1.350000023841858,1.2899999618530273,1.2899999618530273,26394,0.0,0.0,1.9355000019073487,2.7578749895095824,2.7412083288033804,-33.35055744862878,-29.819153904016225,0.6080041611969542,15.176665754115234,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-03,1.309999942779541,1.315000057220459,1.2799999713897705,1.309999942779541,11080,0.0,0.0,1.803499984741211,2.7231249868869782,2.7275416612625123,-27.363462497200054,-33.77094355103634,-0.16192875944889096,16.262543024782374,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-06,1.309999942779541,1.3450000286102295,1.2050000429153442,1.3350000381469727,94524,0.0,0.0,1.6769999980926513,2.6877499878406526,2.714083327849706,-20.39355756318753,-37.60580389993942,-0.9702480295590888,17.68114798957049,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-07,1.2899999618530273,1.2999999523162842,1.1799999475479126,1.2699999809265137,56359,0.0,0.0,1.5460000038146973,2.6499999880790712,2.6993333280086516,-17.852524075495722,-41.66037695210105,-1.8276120039600465,16.88042580315127,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-08,1.25,1.2699999809265137,1.190000057220459,1.2350000143051147,60872,0.0,0.0,1.415500009059906,2.6093749910593034,2.6846249947945275,-12.7516774001767,-45.75329288009813,-2.802998701164352,16.448473710293754,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-10,1.2450000047683716,1.2949999570846558,1.1699999570846558,1.2549999952316284,19755,0.0,0.0,1.3009999990463257,2.567499989271164,2.669999994834264,-3.535742032929803,-49.328140039617274,-3.8389515266445815,17.743765593307984,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-13,1.2549999952316284,1.2549999952316284,1.159999966621399,1.225000023841858,121256,0.0,0.0,1.2930000066757201,2.524124988913536,2.6555416613817213,-5.259086038884791,-48.77432724786467,-4.948770880883379,17.31026186550571,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-14,1.2000000476837158,1.215000033378601,1.1699999570846558,1.215000033378601,30340,0.0,0.0,1.2800000071525575,2.480499988794327,2.6399999956289926,-5.078122922714119,-48.39749998246462,-6.041666935558614,17.15976693921378,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-15,1.215000033378601,1.215000033378601,1.1749999523162842,1.2000000476837158,53228,0.0,0.0,1.2675000071525573,2.4354999899864196,2.625416662295659,-5.325440559206018,-47.957297788384516,-7.233772644041073,16.92211098352827,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-16,1.25,1.2999999523162842,1.2200000286102295,1.2899999618530273,90375,0.0,0.0,1.2625,2.388749986886978,2.61149999499321,2.178214800239793,-47.14808971510278,-8.529581027504879,23.74605662327383,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-17,1.2899999618530273,1.3949999809265137,1.2699999809265137,1.2799999713897705,56440,0.0,0.0,1.2615000009536743,2.335999983549118,2.5967499951521558,1.4665057805874357,-45.99743108572032,-10.041398366798084,23.514937380295663,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-20,0.9952539801597595,1.0386970043182373,0.9952539801597595,1.0189499855041504,10835,0.0,0.0,1.2323950052261352,2.277973735332489,2.579574579000473,-17.31952976252279,-45.89950770234596,-11.691883077280423,18.463021099806525,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-21,1.0347479581832886,1.1176860332489014,1.0347479581832886,1.0663429498672485,53433,0.0,0.0,1.2055292963981628,2.220882311463356,2.562794104218483,-11.545662718174514,-45.71845206854611,-13.34136800893695,21.749815743373816,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-22,1.1374330520629883,1.2164210081100464,1.0663429498672485,1.1334830522537231,142442,0.0,0.0,1.1918776035308838,2.1689693868160247,2.5472397963205973,-4.899374827093774,-45.0486663954017,-14.850208058580568,26.283344612338595,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-23,1.1334830522537231,1.2954100370407104,1.0860899686813354,1.1729780435562134,203860,0.0,0.0,1.1856754064559936,2.1185438364744185,2.532514612873395,-1.070897045738078,-44.03347308455325,-16.34623446177413,28.893144436044665,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-24,1.2085230350494385,1.2085230350494385,1.1058379411697388,1.1492810249328613,114512,0.0,0.0,1.1751035094261169,2.0667758613824843,2.5181752890348434,-2.197464673207078,-43.143156866556396,-17.92565551802273,28.24696993912093,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-27,1.658756971359253,1.658756971359253,1.1492810249328613,1.3980950117111206,202485,0.0,0.0,1.1924130082130433,2.0262282371520994,2.503826081752777,17.249225065593127,-41.151101028529666,-19.074721206927453,42.729694419672064,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-28,1.7000000476837158,4.03000020980835,1.4600000381469727,3.799999952316284,2243389,0.0,0.0,1.4509130001068116,2.040228235721588,2.510909414291382,161.90405296778928,-28.884770110357156,-18.745446406421937,81.51580621315709,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-29,3.700000047683716,3.700000047683716,2.1500000953674316,2.380000114440918,1045143,0.0,0.0,1.5689130067825316,2.02272824048996,2.506159414847692,51.69739202568876,-22.43579857260023,-19.289721615219438,56.95685138259324,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-30,2.380000114440918,2.380000114440918,1.7999999523162842,1.9700000286102295,643960,0.0,0.0,1.636913013458252,1.9889782428741456,2.4979927480220794,20.3484859863308,-17.70080847677583,-20.376940867861745,52.07815308087047,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-05-31,1.9700000286102295,1.9700000286102295,1.399999976158142,1.5149999856948853,943066,0.0,0.0,1.6604130148887635,1.9496032446622849,2.485701081156731,-8.757642098078827,-14.833286237355212,-21.56726891090906,47.2420161790831,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-03,1.5199999809265137,1.7400000095367432,1.4199999570846558,1.4199999570846558,434020,0.0,0.0,1.700518012046814,1.9078532457351685,2.473784414927165,-16.496035500648127,-10.86746237698489,-22.87714183083569,46.275757231693674,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-04,1.399999976158142,1.5299999713897705,1.3200000524520874,1.3200000524520874,270819,0.0,0.0,1.7258837223052979,1.8658532470464706,2.4597844153642656,-23.517440057379034,-7.501636313720588,-24.1456594573082,45.22712165735066,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-05,1.350000023841858,1.6699999570846558,1.340000033378601,1.4600000381469727,402737,0.0,0.0,1.758535420894623,1.8268532484769822,2.4469510823488236,-16.97636449061548,-3.7396450776390893,-25.341652244090255,47.036626627237005,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-07,1.4600000381469727,1.8200000524520874,1.4299999475479126,1.7000000476837158,471028,0.0,0.0,1.811237621307373,1.794353249669075,2.43536775012811,-6.141522918641932,0.9409725560678728,-26.321055636271574,50.081199070603574,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-10,1.6699999570846558,1.6799999475479126,1.3700000047683716,1.4500000476837158,663291,0.0,0.0,1.8413095235824586,1.7566032499074935,2.4229510833819705,-21.25169456232484,4.8221630968419245,-27.501497576434126,47.04731520897325,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-11,1.440000057220459,1.649999976158142,1.3799999952316284,1.5099999904632568,543350,0.0,0.0,1.8525000214576721,1.7203532487154007,2.4111177494128544,-18.48853047380335,7.681374324775813,-28.64914004575952,47.863635308965385,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-12,1.5,1.6299999952316284,1.4299999475479126,1.5700000524520874,364309,0.0,0.0,1.6295000314712524,1.6883532524108886,2.3996177494525908,-3.651425459958006,-3.4858357310945784,-29.640741622450424,48.71506320748358,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-13,1.5700000524520874,1.6399999856948853,1.4800000190734863,1.600000023841858,158250,0.0,0.0,1.5515000224113464,1.657103255391121,2.388784415523211,3.126007136959793,-6.372761180464235,-30.629853216445714,49.1621053973672,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-14,1.4500000476837158,1.649999976158142,1.3799999952316284,1.4199999570846558,387778,0.0,0.0,1.496500015258789,1.6216032564640046,2.3769510825475058,-5.111931666830233,-7.714787245679937,-31.778013086998598,46.54073475306208,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-17,1.4199999570846558,1.5299999713897705,1.3899999856948853,1.4700000286102295,349941,0.0,0.0,1.4920000195503236,1.5873532593250275,2.3665344158808392,-1.4745302045454864,-6.00705855577793,-32.92498732860369,47.38006126030639,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-18,1.4700000286102295,1.5499999523162842,1.309999942779541,1.5199999809265137,633554,0.0,0.0,1.5020000219345093,1.5596032559871673,2.3559510827064516,1.198399382765734,-3.6934543340766126,-33.801543358211916,48.25496502707443,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-19,1.5499999523162842,1.600000023841858,1.4600000381469727,1.5099999904632568,135769,0.0,0.0,1.5210000157356263,1.5323532581329347,2.344867750008901,-0.7232100695968308,-0.7409024216218607,-34.650759808218695,48.08277256753566,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-20,1.5,1.5099999904632568,1.409999966621399,1.4600000381469727,100978,0.0,0.0,1.5210000157356263,1.5043532609939576,2.334367750088374,-4.010517880182348,1.1065721844262695,-35.55628666747105,47.176308144842785,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-24,1.4500000476837158,1.4900000095367432,1.3600000143051147,1.4299999475479126,219975,0.0,0.0,1.494000005722046,1.4766032606363297,2.3236177494128545,-4.28380575160723,1.1781597365712997,-36.45240225035092,46.608548527979174,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-25,1.4199999570846558,1.4500000476837158,1.340000033378601,1.350000023841858,74186,0.0,0.0,1.4840000033378602,1.4503532588481902,2.3129510819911956,-9.029648193706553,2.3198999474369995,-37.29425277772861,45.051502270634764,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-26,1.3300000429153442,1.409999966621399,1.3300000429153442,1.399999976158142,261332,0.0,0.0,1.4730000019073486,1.452728259563446,2.3030344158411027,-4.9558741109762865,1.3954256214437712,-36.92112242999686,46.25987062966707,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-27,1.399999976158142,1.440000057220459,1.3700000047683716,1.440000057220459,101120,0.0,0.0,1.4600000023841857,1.4551032602787017,2.2933677504460017,-1.3698592555525158,0.336521966457973,-36.551682127922085,47.25910413623678,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-06-28,1.440000057220459,1.440000057220459,1.3600000143051147,1.3600000143051147,54467,0.0,0.0,1.4360000014305114,1.4559782594442368,2.2817844172318775,-5.292478206802728,-1.3721535939246272,-36.19124364033736,45.43934311937656,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-01,1.4600000381469727,1.4600000381469727,1.3600000143051147,1.4600000381469727,26167,0.0,0.0,1.4400000095367431,1.458978259563446,2.2720344165960946,1.3888908665121238,-1.3007904608792107,-35.7853803223082,48.12812390126937,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-02,1.440000057220459,1.4500000476837158,1.3700000047683716,1.409999966621399,89110,0.0,0.0,1.4340000033378602,1.4619782596826554,2.2611177494128545,-1.6736427238910303,-1.9137258820023995,-35.342674654502716,46.884022229666336,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-03,1.399999976158142,1.399999976158142,1.25,1.340000033378601,335391,0.0,0.0,1.4160000085830688,1.4627282619476318,2.2507010837395987,-5.367229854787764,-3.1945956456973104,-35.010105406033276,45.125333232185056,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-04,1.3300000429153442,1.3300000429153442,1.25,1.309999942779541,107510,0.0,0.0,1.3960000038146974,1.462103259563446,2.2402010838190716,-6.1604628080339054,-4.521107200628615,-34.73339201002137,44.35737144644373,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-05,1.2799999713897705,1.3600000143051147,1.2699999809265137,1.2899999618530273,43139,0.0,0.0,1.3789999961853028,1.462603259086609,2.229617750644684,-6.4539546467349,-5.716058841104738,-34.40116546149205,43.8219416904445,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-08,1.2200000286102295,1.2899999618530273,1.2000000476837158,1.25,314246,0.0,0.0,1.3610000014305115,1.462978258728981,2.218867750962575,-8.155767914316112,-6.970592808882007,-34.0664508691732,42.71149889167084,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-09,1.2400000095367432,1.4500000476837158,1.2400000095367432,1.340000033378601,504177,0.0,0.0,1.3600000023841858,1.4651032596826554,2.2087010850509006,-1.4705859537149455,-7.173778135012489,-33.66674786376122,46.02555989264365,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-10,1.350000023841858,1.350000023841858,1.2300000190734863,1.2999999523162842,508795,0.0,0.0,1.35,1.466978257894516,2.1982010851303735,-3.7037072358308083,-7.97409622569385,-33.264601322516825,44.7855258702819,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-11,1.3300000429153442,1.340000033378601,1.25,1.2999999523162842,93692,0.0,0.0,1.3359999895095824,1.469103255867958,2.188534417748451,-2.694613583531023,-9.06017094623734,-32.872736935096455,44.7855258702819,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-12,1.2999999523162842,1.4600000381469727,1.2699999809265137,1.3799999952316284,712353,0.0,0.0,1.337999987602234,1.473603254556656,2.1786177515983582,3.1390140522094248,-9.202155772601035,-32.36063309061277,48.03310684916938,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-15,1.3799999952316284,1.5199999809265137,1.3200000524520874,1.4900000095367432,1142083,0.0,0.0,1.3409999847412108,1.4786032557487487,2.170117751757304,11.111113086573724,-9.306301096831893,-31.865298343768906,52.19655754750054,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-16,1.5800000429153442,1.5800000429153442,1.4900000095367432,1.5299999713897705,188195,0.0,0.0,1.352999985218048,1.4848532557487488,2.1604510843753815,13.08203903218796,-8.879885606218554,-31.271146730080122,53.65074680772746,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-17,1.5299999713897705,1.5700000524520874,1.5,1.5099999904632568,93866,0.0,0.0,1.3699999809265138,1.4971295058727265,2.149867751200994,10.21897894057362,-8.4915516291361,-30.3617859732825,52.786105324257655,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-18,1.5099999904632568,1.8200000524520874,1.3899999856948853,1.7599999904632568,1174700,0.0,0.0,1.4149999856948852,1.5144709318876266,2.1413677513599394,24.38162602517253,-6.568032710192827,-29.275532849235415,61.20302642343259,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-19,1.7599999904632568,1.7599999904632568,1.659999966621399,1.7200000286102295,146979,0.0,0.0,1.4579999923706055,1.5291338562965393,2.132284418741862,17.969824253128447,-4.651905628341478,-28.286590529100568,59.37904304950399,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-22,1.7000000476837158,1.809999942779541,1.6399999856948853,1.7200000286102295,140986,0.0,0.0,1.5049999952316284,1.5428094059228896,2.1241177519162497,14.285716548823729,-2.4506857779133178,-27.36704900041154,59.379043049504,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-23,1.7200000286102295,1.7200000286102295,1.600000023841858,1.649999976158142,230280,0.0,0.0,1.5359999895095826,1.5553273797035216,2.1156177510817846,7.421874181454756,-1.24265736244052,-26.483535179820088,55.992283884920894,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-24,1.6799999475479126,1.6799999475479126,1.5,1.6100000143051147,922961,0.0,0.0,1.5669999957084655,1.5606250047683716,2.108034418026606,2.744098194921071,0.4084896064471323,-25.967764500291263,54.09364123716676,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-25,1.5700000524520874,1.5700000524520874,1.350000023841858,1.5099999904632568,473819,0.0,0.0,1.5879999995231628,1.5033750057220459,2.0997844179471334,-4.911839362929942,5.629000979730471,-28.4033640371601,49.5683673086675,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-26,1.4299999475479126,1.5499999523162842,1.4199999570846558,1.5,98095,0.0,0.0,1.6,1.4813750028610229,2.090701085329056,-6.250000000000005,8.007762849371247,-29.14458153505627,49.1257867411052,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-29,1.5199999809265137,1.659999966621399,1.5099999904632568,1.600000023841858,444637,0.0,0.0,1.6110000014305115,1.4721250027418136,2.0810344189405443,-0.6828043189873352,9.433641737627243,-29.25993970386741,53.58849578054896,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-30,1.649999976158142,1.649999976158142,1.4900000095367432,1.5199999809265137,689772,0.0,0.0,1.6100000023841858,1.4722500026226044,2.0728677521149317,-5.590063436297805,9.356427204360628,-28.9752083257372,49.823134013192444,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-07-31,1.5399999618530273,1.5700000524520874,1.4700000286102295,1.5499999523162842,46723,0.0,0.0,1.6139999985694886,1.475500002503395,2.0649510850509007,-3.965306462820855,9.386648311156126,-28.545522788157268,51.207663040790436,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-01,1.559999942779541,1.5800000429153442,1.5099999904632568,1.5199999809265137,53950,0.0,0.0,1.5899999976158141,1.4805000007152558,2.057201084494591,-4.402516779513499,7.396149736417221,-28.03328698035457,49.72991321085213,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-02,1.5199999809265137,1.5700000524520874,1.4600000381469727,1.5,134200,0.0,0.0,1.5679999947547913,1.4814999997615814,2.0484510848919553,-4.336734373868757,5.838676679522809,-27.677062406412183,48.72049513103529,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-05,1.4700000286102295,1.4700000286102295,1.3200000524520874,1.409999966621399,484518,0.0,0.0,1.5369999885559082,1.4742499977350234,2.039784417549769,-8.262851195843696,4.256400944025187,-27.72520541627027,44.35719373602994,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-06,1.4600000381469727,1.4600000381469727,1.3899999856948853,1.4199999570846558,99027,0.0,0.0,1.5139999866485596,1.473499995470047,2.0313677499691645,-6.208720633610138,2.748557265220293,-27.46266669378727,44.94715686570248,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-07,1.440000057220459,1.4600000381469727,1.4199999570846558,1.440000057220459,29914,0.0,0.0,1.496999990940094,1.4717499971389771,2.023034416635831,-3.807610825958646,1.7156442228776478,-27.250372755081575,46.17631163005805,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-08,1.3799999952316284,1.4500000476837158,1.340000033378601,1.440000057220459,47922,0.0,0.0,1.4899999976158143,1.4684999972581863,2.0144510835409166,-3.3557007030443895,1.4640790192557251,-27.101729634609978,46.17631163005805,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-09,1.4600000381469727,1.4700000286102295,1.409999966621399,1.4600000381469727,77685,0.0,0.0,1.4860000014305115,1.4649999976158141,2.005951083699862,-1.7496610537355124,1.4334473616978431,-26.96731193894792,47.534827449772585,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-12,1.409999966621399,1.4500000476837158,1.350000023841858,1.3899999856948853,347683,0.0,0.0,1.4649999976158141,1.46424999833107,1.9975344161192576,-5.119454746961514,0.051220712692437206,-26.697132899679126,43.40541185547486,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-13,1.3700000047683716,1.3799999952316284,1.340000033378601,1.3799999952316284,56050,0.0,0.0,1.4509999990463256,1.461999997496605,1.9888677487770716,-4.893177385345428,-0.7523938761364375,-26.4908389008988,42.83295779425596,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-14,1.3799999952316284,1.3799999952316284,1.2999999523162842,1.3300000429153442,700645,0.0,0.0,1.4290000081062317,1.4572499990463257,1.9804510831832887,-6.927919148306111,-1.9385823268884346,-26.418278571970227,39.992856242576224,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-15,1.3300000429153442,1.440000057220459,1.309999942779541,1.350000023841858,621049,0.0,0.0,1.412000012397766,1.4532499998807906,1.9726177503665288,-4.390933995150881,-2.8384646472670405,-26.328859222180036,41.659230812215114,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-16,1.399999976158142,1.399999976158142,1.2899999618530273,1.350000023841858,333450,0.0,0.0,1.397000014781952,1.4504999995231629,1.962201084693273,-3.3643514991250663,-3.6883822653428857,-26.07791266459819,41.659230812215114,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-19,1.309999942779541,1.3799999952316284,1.309999942779541,1.3600000143051147,73598,0.0,0.0,1.3920000195503235,1.4487500011920929,1.9534510840972266,-2.298850919236778,-3.917168703715139,-25.836381930104878,42.583808537376534,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-20,1.350000023841858,1.3700000047683716,1.3200000524520874,1.350000023841858,69456,0.0,0.0,1.3850000262260438,1.4487500011920929,1.9448677500089009,-2.52707593656562,-4.400343393518059,-25.509073756533702,41.869228438780766,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-21,1.309999942779541,1.3700000047683716,1.309999942779541,1.3600000143051147,43535,0.0,0.0,1.3770000219345093,1.4477500021457672,1.9342844158411026,-1.2345684356280353,-4.886892081256885,-25.153199276734657,42.90108412563387,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-22,1.3300000429153442,1.3600000143051147,1.2799999713897705,1.2899999618530273,155199,0.0,0.0,1.362000012397766,1.4439999997615813,1.9225344151258468,-5.286347275282652,-5.678669485966365,-24.890811399750216,37.83790368374306,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-23,1.2999999523162842,1.3300000429153442,1.25,1.2999999523162842,446740,0.0,0.0,1.3460000038146973,1.4424999982118607,1.911117747426033,-3.4175372487402997,-6.689774316588276,-24.520611032225762,38.94644528677655,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-26,1.2899999618530273,1.2899999618530273,1.2200000286102295,1.2699999809265137,259501,0.0,0.0,1.33400000333786,1.4377499967813492,1.8980344146490098,-4.79760286740698,-7.216135884246311,-24.250583356929162,36.824800449379865,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-27,1.2200000286102295,1.2899999618530273,1.2200000286102295,1.2699999809265137,114431,0.0,0.0,1.3230000019073487,1.434249997138977,1.8847010821104049,-4.0060484432672485,-7.756666930698859,-23.900399339031132,36.824800449379865,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-28,1.2799999713897705,1.3300000429153442,1.2599999904632568,1.309999942779541,192052,0.0,0.0,1.3209999918937683,1.4334999948740006,1.8731177479028702,-0.8327062211754993,-7.847924895885379,-23.469840778619638,41.73313978149658,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-29,1.309999942779541,1.340000033378601,1.2300000190734863,1.2599999904632568,143251,0.0,0.0,1.3119999885559082,1.4322499960660935,1.8607010811567306,-3.963414523340558,-8.39588115485924,-23.02632536894559,37.78162767060128,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-08-30,1.25,1.2699999809265137,1.25,1.2699999809265137,42703,0.0,0.0,1.3039999842643737,1.4317499965429306,1.84811774790287,-2.6073622506246013,-8.922647989315104,-22.529286991178346,39.02513341302613,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-02,1.2400000095367432,1.2799999713897705,1.2200000286102295,1.2799999713897705,225164,0.0,0.0,1.2959999799728394,1.432499995827675,1.8349510818719863,-1.2345685825862631,-9.528796946066869,-21.932523979535056,40.30987656076587,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-03,1.2799999713897705,1.2799999713897705,1.2599999904632568,1.2599999904632568,73624,0.0,0.0,1.2869999766349793,1.4304999947547912,1.8210344145695367,-2.0979010615304987,-10.03145883579048,-21.445746257742286,38.5599624521496,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-04,1.2599999904632568,1.3200000524520874,1.2400000095367432,1.3200000524520874,137780,0.0,0.0,1.2829999804496766,1.4309999972581864,1.8073677480220796,2.8838715951844947,-10.342419084002772,-20.824082491002564,46.117186986834824,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-05,1.340000033378601,1.7000000476837158,1.340000033378601,1.5499999523162842,3148060,0.0,0.0,1.308999979496002,1.4372499972581863,1.7956177473068238,18.410998975956677,-8.923292259999597,-19.95790866882103,64.26336428328034,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-06,1.6399999856948853,1.649999976158142,1.4600000381469727,1.559999942779541,1037389,0.0,0.0,1.3349999785423279,1.4417499959468842,1.7836177468299865,16.853930176305184,-7.404197517229552,-19.167097405859625,64.81813102656969,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-09,1.5499999523162842,1.5800000429153442,1.399999976158142,1.5800000429153442,539113,0.0,0.0,1.365999984741211,1.4439999967813493,1.770451079805692,15.666183057438,-5.401662895706298,-18.438864916853333,65.956411671026,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-10,1.559999942779541,1.5800000429153442,1.4800000190734863,1.5399999618530273,101829,0.0,0.0,1.3929999828338624,1.4442499965429305,1.7550344119469325,10.552762442976789,-3.5485555708322067,-17.708166477444507,61.65961652825702,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-11,1.559999942779541,1.5800000429153442,1.409999966621399,1.5199999809265137,378440,0.0,0.0,1.4139999866485595,1.444499996304512,1.7398677458365759,7.496463598220653,-2.1114579255092507,-16.976448367346624,59.56999057677902,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-12,1.5,1.5,1.4299999475479126,1.4800000190734863,265042,0.0,0.0,1.4359999895095825,1.4374999970197677,1.7242844134569169,3.06406893351932,-0.10434834875095794,-16.632083094817972,55.51758435103166,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-13,1.4299999475479126,1.5299999713897705,1.4299999475479126,1.4700000286102295,201697,0.0,0.0,1.455999994277954,1.4312499970197679,1.709784413377444,0.9615408233032477,1.729257453954379,-16.29061618402929,54.51906037634188,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-16,1.5499999523162842,1.5499999523162842,1.4500000476837158,1.5,139494,0.0,0.0,1.477999997138977,1.425749996304512,1.6957010795672736,1.488498166685336,3.66473792529511,-15.91973293616411,57.01672094273844,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-17,1.5099999904632568,1.6699999570846558,1.4600000381469727,1.600000023841858,460370,0.0,0.0,1.5120000004768372,1.4244999974966048,1.682201079527537,5.820107363575941,6.142506362513417,-15.319279316079747,64.09493445535698,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-18,1.649999976158142,1.6699999570846558,1.5399999618530273,1.6699999570846558,58679,0.0,0.0,1.546999990940094,1.4259999960660934,1.670951079328855,7.950870514861226,8.485273156227441,-14.659380893493735,68.05992578614396,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-19,1.659999966621399,1.690000057220459,1.590000033378601,1.6699999570846558,270659,0.0,0.0,1.5589999914169312,1.4299999952316285,1.6578677455584208,7.119946522054805,9.020978784297661,-13.744627756784029,68.05992578614396,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-20,1.649999976158142,1.7899999618530273,1.6100000143051147,1.7699999809265137,371516,0.0,0.0,1.5799999952316284,1.4367499947547913,1.6469510793685913,12.025315586601078,9.97041941881374,-12.763043617202463,72.99989089775082,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-23,1.7999999523162842,1.7999999523162842,1.659999966621399,1.7599999904632568,245602,0.0,0.0,1.5979999899864197,1.4407499939203263,1.6339510798454284,10.137672183478166,10.914454050297175,-11.824165870582789,71.80392089650994,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-24,1.7300000190734863,1.75,1.649999976158142,1.7300000190734863,197287,0.0,0.0,1.6169999957084655,1.4459999948740005,1.6226177473862966,6.988251308900681,11.825726240708965,-10.884741819001482,68.19437501263158,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-25,1.7400000095367432,1.7400000095367432,1.649999976158142,1.6699999570846558,376064,0.0,0.0,1.6319999933242797,1.4489999949932098,1.6107844144105912,2.3284291615083017,12.62939951438216,-10.043828210032727,61.53211204064706,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-26,1.6299999952316284,1.6699999570846558,1.5299999713897705,1.5800000429153442,124127,0.0,0.0,1.6419999957084657,1.4504999965429306,1.5989510814348857,-3.7758802043340207,13.202343993240213,-9.284279338848586,53.14502895777326,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-27,1.6299999952316284,1.6799999475479126,1.559999942779541,1.6699999570846558,112554,0.0,0.0,1.6619999885559082,1.454749995470047,1.5877010812362036,0.4813458835038014,14.246433664287203,-8.373810872676318,59.14246912487632,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-09-30,1.6699999570846558,1.899999976158142,1.559999942779541,1.75,301342,0.0,0.0,1.6869999885559082,1.463249996304512,1.5772844145695368,3.734440537727602,15.291303114060097,-7.229794272464576,63.60228727976997,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-01,1.8600000143051147,2.0,1.7699999809265137,1.7699999809265137,199910,0.0,0.0,1.7039999842643738,1.4719999969005584,1.567367747426033,3.8732392765034214,15.760868739967007,-6.08458038530458,64.6414034360121,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-02,1.850000023841858,1.8799999952316284,1.7599999904632568,1.7899999618530273,118686,0.0,0.0,1.7159999847412108,1.4807499945163727,1.5576177467902501,4.312353016889822,15.887218713221952,-4.934956116946997,65.69607798093907,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-03,1.7799999713897705,1.9199999570846558,1.75,1.8799999952316284,200236,0.0,0.0,1.7369999885559082,1.491749992966652,1.549534414211909,8.23258535508721,16.44042210461326,-3.7291473306609992,70.02849078020607,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-04,1.8799999952316284,2.0999999046325684,1.7999999523162842,2.059999942779541,1148577,0.0,0.0,1.765999984741211,1.5067499905824662,1.542951081196467,16.64778938723563,17.20590647281346,-2.3462241321305597,76.43785868816094,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-07,2.1600000858306885,2.200000047683716,2.0,2.180000066757202,546782,0.0,0.0,1.8079999923706054,1.5264999926090241,1.5374510824680327,20.575225440064266,18.440877898758078,-0.7122886694664192,79.57392671257685,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-08,2.259999990463257,2.259999990463257,1.9500000476837158,2.0999999046325684,491934,0.0,0.0,1.8449999809265136,1.5444999903440475,1.5312844157218932,13.821134219090888,19.45613418330471,0.8630385372219742,72.63327574594922,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-09,2.0999999046325684,2.140000104904175,1.940000057220459,2.0999999046325684,279098,0.0,0.0,1.8879999756813048,1.5637499868869782,1.5268677473068237,11.22880994078197,20.73541112795304,2.4155490641026023,72.63327574594922,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-10,2.180000066757202,2.180000066757202,2.0,2.0799999237060547,394417,0.0,0.0,1.937999963760376,1.581999984383583,1.5225344141324362,7.327139453096311,22.503159474777508,3.9056962981707875,70.84173501772855,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-11,2.0799999237060547,2.1600000858306885,2.059999942779541,2.140000104904175,152394,0.0,0.0,1.9849999785423278,1.601749986410141,1.5188677489757538,7.808570681984106,23.92695460489004,5.4568435922270835,72.99383128769513,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-14,2.240000009536743,2.240000009536743,1.9500000476837158,2.0399999618530273,872412,0.0,0.0,2.0139999747276307,1.6187499850988387,1.5147010823090872,1.2909626341436684,24.416988001062965,6.869269719615841,64.45515730902653,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-15,2.0399999618530273,2.0799999237060547,1.840000033378601,1.899999976158142,418343,0.0,0.0,2.0269999742507934,1.632499983906746,1.5105344146490096,-6.265416857718126,24.165390152100766,8.074332373690176,54.7917270730972,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-16,1.899999976158142,1.940000057220459,1.8799999952316284,1.9299999475479126,125667,0.0,0.0,2.040999972820282,1.6467499822378158,1.515742747982343,-5.438511844710509,23.941095784723103,8.643104803230026,56.30353789979953,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-17,1.9800000190734863,2.0,1.8700000047683716,1.8899999856948853,45784,0.0,0.0,2.0419999718666078,1.6617499828338622,1.5202844142913818,-7.443682089416395,22.882502961383334,9.305204158684923,53.7238334712151,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-18,1.8899999856948853,2.059999942779541,1.8799999952316284,2.059999942779541,150605,0.0,0.0,2.0419999718666078,1.6807499825954437,1.5264094134171804,0.8814873242372943,21.49338051536466,10.111348097149135,61.745898649072224,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-21,2.059999942779541,2.0799999237060547,1.8799999952316284,1.940000057220459,170978,0.0,0.0,2.0179999709129333,1.6974999845027923,1.5314094136158625,-3.8652088610877184,18.88070629373333,10.845602058483351,54.55650804896225,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-22,1.9299999475479126,2.0199999809265137,1.850000023841858,1.9700000286102295,101132,0.0,0.0,2.0049999833106993,1.7149999856948852,1.5370760808388393,-1.7456336654266256,16.90962099328016,11.575478082968168,55.937767163722796,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-23,1.9500000476837158,1.9700000286102295,1.8899999856948853,1.940000057220459,30279,0.0,0.0,1.9889999985694886,1.7307499885559081,1.5423260817925135,-2.463546575378127,14.92127758030826,12.21686574504437,54.16478183201042,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-24,1.940000057220459,1.940000057220459,1.7699999809265137,1.9199999570846558,158532,0.0,0.0,1.9730000019073486,1.7472499877214431,1.5472010811169943,-2.686266840925309,12.92030423650493,12.92972898261062,52.95963215541186,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-25,1.7000000476837158,1.8899999856948853,1.7000000476837158,1.840000033378601,120547,0.0,0.0,1.9429999947547913,1.7614999890327454,1.551951081554095,-5.30107882934858,10.303718810790862,13.502288182228794,48.32769986706589,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-28,1.840000033378601,1.840000033378601,1.7100000381469727,1.75,137181,0.0,0.0,1.9139999985694884,1.7732499897480012,1.5562427481015524,-8.568442982866301,7.9374036168182585,13.944305405514285,43.69738551390195,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-29,1.9199999570846558,1.9199999570846558,1.7699999809265137,1.7799999713897705,97726,0.0,0.0,1.9019999980926514,1.7862499892711639,1.5606177479028702,-6.414302146436593,6.480056515981649,14.457880007547919,45.56944634245213,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-30,1.7999999523162842,1.8899999856948853,1.75,1.7899999618530273,163217,0.0,0.0,1.8879999995231629,1.7979999870061874,1.5653260807196299,-5.190679962652894,5.005562467596715,14.864245166067247,46.2114604553764,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-10-31,1.7799999713897705,1.8200000524520874,1.7300000190734863,1.7300000190734863,16082,0.0,0.0,1.8720000028610229,1.8024999886751174,1.5696177472670874,-7.585469207826631,3.8557567058288695,14.836876163862755,42.93889304604768,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-01,1.7400000095367432,1.7699999809265137,1.7300000190734863,1.75,12557,0.0,0.0,1.841000008583069,1.807249990105629,1.5742010802030564,-4.94296622264045,1.8674792453847167,14.804265657886065,44.3535139787551,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-04,1.7599999904632568,1.8799999952316284,1.7000000476837158,1.7200000286102295,164352,0.0,0.0,1.819000005722046,1.810749989748001,1.5777844140926998,-5.442549576711997,0.4556132000968828,14.76536170432812,42.64566024787722,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-05,1.7400000095367432,1.809999942779541,1.659999966621399,1.7200000286102295,161727,0.0,0.0,1.794000005722046,1.815249991416931,1.5814510812362035,-4.124859357624869,-1.1706368706988948,14.783821830136503,42.64566024787722,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-06,1.7400000095367432,1.7799999713897705,1.690000057220459,1.75,104781,0.0,0.0,1.775,1.8209999918937683,1.5875431646903355,-1.4084507042253471,-2.5260841350103562,14.705542022157905,45.09745700910002,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-07,1.6399999856948853,1.850000023841858,1.6399999856948853,1.7999999523162842,34285,0.0,0.0,1.7629999995231629,1.8289999902248382,1.5936569730440775,2.0986927284814882,-3.608528761859749,14.767482661668843,49.00981178728902,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-08,1.7300000190734863,1.7799999713897705,1.649999976158142,1.7400000095367432,229880,0.0,0.0,1.7529999971389771,1.8357499897480012,1.5987112810214361,-0.7415851468026752,-4.507694025393043,14.826861581605788,44.87708810750052,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-11,1.7300000190734863,1.8200000524520874,1.7000000476837158,1.7799999713897705,132066,0.0,0.0,1.755999994277954,1.8427499890327455,1.6037697970867157,1.3667412978372446,-4.707637784348936,14.901153044541845,48.023761069637004,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-12,1.7899999618530273,1.8200000524520874,1.7400000095367432,1.7999999523162842,68097,0.0,0.0,1.7579999923706056,1.847749987244606,1.6091924548149108,2.3890762302588553,-4.857258584416877,14.824673811755723,49.573757690026945,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-13,1.75,1.899999976158142,1.7400000095367432,1.7899999618530273,178904,0.0,0.0,1.7579999923706056,1.8507499873638154,1.6124583293994268,1.8202485563876978,-5.011481595378623,14.778159138732114,48.79030261076589,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-14,1.8200000524520874,1.8200000524520874,1.649999976158142,1.7999999523162842,111167,0.0,0.0,1.7649999856948853,1.853999987244606,1.5957916627327602,1.9830009577943053,-4.800431616075229,16.180578614483384,49.64728100182615,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-15,1.7999999523162842,1.7999999523162842,1.659999966621399,1.7799999713897705,159760,0.0,0.0,1.7679999828338624,1.8542499870061875,1.5907916615406672,0.6787323909739961,-4.65147659575188,16.561460047531508,47.92005315237967,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-18,1.7899999618530273,1.8700000047683716,1.7300000190734863,1.75,214443,0.0,0.0,1.7709999799728393,1.853999987244606,1.5889583279689152,-1.1857696335581762,-4.476807327011927,16.680214616734478,45.37027988296011,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-19,1.840000033378601,1.840000033378601,1.7200000286102295,1.7200000286102295,99758,0.0,0.0,1.7709999799728393,1.8537499874830246,1.5906666616598766,-2.879726252927003,-4.463924912686911,16.539186503639794,42.91137683394048,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-20,1.7200000286102295,1.7599999904632568,1.7000000476837158,1.7300000190734863,66624,0.0,0.0,1.768999981880188,1.8552499890327454,1.5932499955097834,-2.2046333073022675,-4.648969554638011,16.4443743456049,44.0008457497888,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-21,1.7999999523162842,1.8200000524520874,1.7100000381469727,1.7599999904632568,71386,0.0,0.0,1.7649999856948853,1.8597499877214432,1.5969166616598764,-0.2832858511134722,-5.094770945133607,16.45880041030889,47.25298476969293,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-22,1.75,1.7599999904632568,1.6799999475479126,1.7300000190734863,49086,0.0,0.0,1.7639999866485596,1.861249989271164,1.5991666615009308,-1.9274358181640436,-5.2249833812321995,16.388743842636735,44.471636163028556,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-25,1.75,1.75,1.6799999475479126,1.6799999475479126,64300,0.0,0.0,1.7539999842643739,1.8594999879598617,1.5989999939997992,-4.218930295344149,-5.673568398956349,16.29143182849163,40.2222428373914,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-26,1.6799999475479126,1.75,1.649999976158142,1.690000057220459,144349,0.0,0.0,1.7429999947547912,1.8574999898672104,1.6009999940792718,-3.0407307913841,-6.164198962962292,16.021236523205022,41.42770854140298,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-27,1.649999976158142,1.7899999618530273,1.649999976158142,1.75,155228,0.0,0.0,1.7389999985694886,1.8564999908208848,1.6029999941587447,0.6325475238389908,-6.329113537966754,15.814098414590264,48.17989309041108,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-28,1.7999999523162842,1.7999999523162842,1.7000000476837158,1.7699999809265137,188348,0.0,0.0,1.7360000014305115,1.8537499904632568,1.604666660229365,1.958524162902378,-6.351988652111569,15.522434434967863,50.23911710816117,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-11-29,1.7300000190734863,1.8200000524520874,1.7000000476837158,1.75,113686,0.0,0.0,1.7330000042915343,1.8459999918937684,1.605916660030683,0.980957626449367,-6.121342800565779,14.949924727631783,48.17738061726257,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-02,1.7799999713897705,1.809999942779541,1.7000000476837158,1.7999999523162842,151705,0.0,0.0,1.7379999995231628,1.8364999890327454,1.6090833266576132,3.5673160420098804,-5.36346256998678,14.133305504291183,53.33347986531227,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-03,1.7799999713897705,1.8200000524520874,1.7100000381469727,1.809999942779541,219290,0.0,0.0,1.746999990940094,1.8292499899864196,1.6119166592756906,3.6061792882749586,-4.496378269595415,13.482913614677017,54.31254934350711,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-04,1.7699999809265137,1.7799999713897705,1.690000057220459,1.75,93952,0.0,0.0,1.7489999890327455,1.8204999923706056,1.6138333261013031,0.05717615629074926,-3.927492646937875,12.80594860242275,47.828704075533324,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-05,1.7899999618530273,1.7899999618530273,1.7100000381469727,1.75,71213,0.0,0.0,1.7479999899864196,1.8122499942779542,1.615833326180776,0.11441704948728,-3.5453168433935303,12.155750529136165,47.828704075533324,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-06,1.75,1.7999999523162842,1.7000000476837158,1.7799999713897705,142112,0.0,0.0,1.752999985218048,1.803249990940094,1.6184999922911325,1.5402159954019674,-2.786635573243457,11.414890301447041,51.20650283043483,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-09,1.7899999618530273,1.7899999618530273,1.7300000190734863,1.7799999713897705,63393,0.0,0.0,1.762999987602234,1.7967499911785125,1.6214166591564814,0.964264543793749,-1.8783917485449089,10.813588908926457,51.20650283043483,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-10,1.7699999809265137,1.840000033378601,1.7300000190734863,1.8300000429153442,123235,0.0,0.0,1.7769999861717225,1.7949999928474427,1.6254166593154271,2.982558084190104,-1.0027858912225656,10.433222310114541,56.633678548008106,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-11,1.7999999523162842,1.8200000524520874,1.6799999475479126,1.7400000095367432,519074,0.0,0.0,1.7759999871253966,1.7902499943971635,1.6282499929269154,-2.0270257798212277,-0.7959786240114074,9.949332238536634,46.588695365120024,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-12,1.7799999713897705,2.0,1.7400000095367432,1.9700000286102295,634176,0.0,0.0,1.7959999918937684,1.792249995470047,1.6326666593551635,9.688198079165307,0.20923400380524568,9.774397927493196,64.10868101620645,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-13,2.0,2.0799999237060547,1.899999976158142,2.0199999809265137,612277,0.0,0.0,1.8229999899864198,1.7912499964237214,1.6381666590770085,10.8063627000657,1.7725048779393202,9.344796300088571,66.66834982608327,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-16,2.059999942779541,2.059999942779541,1.9299999475479126,1.9900000095367432,316187,0.0,0.0,1.8419999957084656,1.7924999952316285,1.6425833255052567,8.03474561200279,2.7615063100985213,9.126883695854984,63.73148259689084,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-17,1.9800000190734863,2.799999952316284,1.8700000047683716,2.799999952316284,3452805,0.0,0.0,1.9409999966621398,1.8132499933242798,1.6541666587193806,44.25553617369048,7.045360750486066,9.617128586551129,84.09899548016902,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-18,2.700000047683716,2.759999990463257,2.2200000286102295,2.4200000762939453,1856568,0.0,0.0,2.0080000042915342,1.8252499938011169,1.6631666590770087,20.517931828778735,10.012327687224758,9.745465605597095,65.51189958687971,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-19,2.380000114440918,2.640000104904175,2.259999990463257,2.5799999237060547,586097,0.0,0.0,2.09099999666214,1.8417499929666519,1.673749992251396,23.385936290028912,13.533324536301558,10.037341388678692,68.65336613392766,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-20,2.5799999237060547,2.799999952316284,2.5399999618530273,2.6600000858306885,496281,0.0,0.0,2.1790000081062315,1.862249994277954,1.68516665995121,22.074349515147272,17.008995290725736,10.5083573355214,70.1189639157404,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-23,2.680000066757202,3.0199999809265137,2.6600000858306885,3.0,1442100,0.0,0.0,2.301000010967255,1.893499994277954,1.6997499932845435,30.37809585837036,21.52099381678067,11.39873521158333,75.38612401734733,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-27,3.0799999237060547,3.119999885559082,2.819999933242798,2.9800000190734863,511925,0.0,0.0,2.416000008583069,1.923499995470047,1.7134166598320006,23.344371212200084,25.60436778127828,12.261076979293804,74.55362242130398,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2024-12-30,2.9800000190734863,3.0,2.740000009536743,2.8399999141693115,498232,0.0,0.0,2.5259999990463258,1.9497499942779541,1.7262499928474426,12.430717151287977,29.555071494269846,12.947139890315027,68.82410924618179,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-02,2.859999895095825,2.859999895095825,2.4000000953674316,2.5399999618530273,778557,0.0,0.0,2.5829999923706053,1.9699999928474425,1.7365833262602488,-1.6647321194187739,31.116751357807427,13.441144058998834,58.45689194837084,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-03,2.5999999046325684,2.880000114440918,2.5,2.559999942779541,437043,0.0,0.0,2.636999988555908,1.9902499914169312,1.7464166591564814,-2.919986579845774,32.495917594680265,13.96192202943261,58.901361602632775,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-07,2.559999942779541,2.619999885559082,2.4000000953674316,2.5199999809265137,314885,0.0,0.0,2.689999985694885,2.010249990224838,1.7549999922513961,-6.3197028131008235,33.81420215273921,14.544159492900926,57.574612409729525,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-08,2.5199999809265137,2.640000104904175,2.4200000762939453,2.5999999046325684,410097,0.0,0.0,2.6699999809265136,2.0322499871253967,1.763916658361753,-2.6217257226217128,31.381473629787532,15.212358673048637,59.53765285910492,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-09,2.619999885559082,2.9200000762939453,2.5,2.8399999141693115,520045,0.0,0.0,2.7119999647140505,2.0594999849796296,1.7749999910593033,4.719762209464379,31.68244644298333,16.028168752301763,64.79971507088968,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-10,2.8399999141693115,2.9200000762939453,2.640000104904175,2.799999952316284,305978,0.0,0.0,2.7339999675750732,2.0844999849796295,1.7836666574080786,2.414044825309554,31.158550600891026,16.86600611846972,63.32166138378699,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-13,2.759999990463257,2.799999952316284,2.559999942779541,2.5999999046325684,435314,0.0,0.0,2.727999949455261,2.1059999823570252,1.7909999897082647,-4.692083841433075,29.534661553135273,17.587939389104676,56.39515678769592,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-14,2.5999999046325684,2.619999885559082,2.359999895095825,2.4200000762939453,519654,0.0,0.0,2.6699999570846558,2.1219999849796296,1.7968333234389624,-9.363291565880122,25.82469255343971,18.09665133092758,50.98926607385401,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-15,2.440000057220459,2.5799999237060547,2.380000114440918,2.4000000953674316,306597,0.0,0.0,2.6119999647140504,2.136999988555908,1.803083324432373,-8.116381018781043,22.227420622455252,18.519203167089085,50.41104577454256,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-16,2.5399999618530273,2.619999885559082,2.2799999713897705,2.359999895095825,556028,0.0,0.0,2.563999962806702,2.1512499868869783,1.8093333234389624,-7.956321008974057,19.186518463017123,18.897383860600215,49.20912056424669,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-17,2.299999952316284,2.4200000762939453,2.2799999713897705,2.4000000953674316,305701,0.0,0.0,2.549999976158142,2.166249990463257,1.8167499909798304,-5.882348321300842,17.714944599391295,19.23764971617972,50.48060700586961,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-20,2.380000114440918,2.5399999618530273,2.3399999141693115,2.4200000762939453,255444,0.0,0.0,2.5359999895095826,2.182249993085861,1.82441665828228,-4.5741290889385855,16.21033325899995,19.613575286058143,51.139232271203085,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-21,2.4200000762939453,2.5199999809265137,2.359999895095825,2.5,165247,0.0,0.0,2.5339999914169313,2.200999993085861,1.8319166580835977,-1.3417518363099767,15.12948656870259,20.14738680243065,53.786954022811805,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-22,2.5,2.5399999618530273,2.359999895095825,2.4600000381469727,141143,0.0,0.0,2.5200000047683715,2.2194999933242796,1.8397499918937683,-2.380951051899454,13.539085935928066,20.641391662114437,52.26201357865959,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-23,2.5799999237060547,2.5799999237060547,2.4000000953674316,2.5,92321,0.0,0.0,2.4860000133514406,2.238749992847443,1.8476666589577992,0.5631531204091045,11.044110387222071,21.1663360375967,53.67638369343936,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-24,2.5,2.859999895095825,2.5,2.759999990463257,384489,0.0,0.0,2.4820000171661376,2.2637499928474427,1.8579999923706054,11.200643488090305,9.641083379714143,21.83799796248355,61.63340727022588,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-27,2.9800000190734863,2.9800000190734863,2.799999952316284,2.859999895095825,609716,0.0,0.0,2.5080000162124634,2.291999989748001,1.8693333248297372,14.035082799359216,9.424084966431915,22.61055635739876,64.18178096897974,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-28,2.880000114440918,3.0999999046325684,2.7799999713897705,2.9800000190734863,551864,0.0,0.0,2.5640000104904175,2.3244999915361406,1.8824166586001714,16.224649254330554,10.303291883258034,23.484882101750916,67.01327634461404,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-29,3.0,3.140000104904175,2.7799999713897705,2.880000114440918,575454,0.0,0.0,2.612000012397766,2.354249992966652,1.8945833265781402,10.26034076459031,10.948285874530967,24.262150940530464,62.574036456291644,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-30,2.9000000953674316,2.9800000190734863,2.680000066757202,2.880000114440918,392311,0.0,0.0,2.6640000343322754,2.3824999958276747,1.9065833270549775,8.10811101069608,11.8153216788069,24.96175551413358,62.574036456291644,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-01-31,2.819999933242798,2.9800000190734863,2.799999952316284,2.9200000762939453,136097,0.0,0.0,2.716000032424927,2.4112499982118605,1.9189166605472565,7.511047180911885,12.638674315772466,25.6568379329301,63.68988373891035,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-03,2.859999895095825,3.0399999618530273,2.819999933242798,2.9800000190734863,258472,0.0,0.0,2.772000026702881,2.441999998688698,1.9315833270549774,7.503607156094011,13.513514667951926,26.424781394853746,65.35830914346079,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-04,3.0,3.0399999618530273,2.9600000381469727,2.9600000381469727,134689,0.0,0.0,2.8180000305175783,2.471000000834465,1.9446666608254115,5.039034992604787,14.042898808819515,27.06547865564024,64.29774167215031,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-05,2.9800000190734863,3.259999990463257,2.9600000381469727,3.259999990463257,395599,0.0,0.0,2.8980000257492065,2.507250002026558,1.9603333274523418,12.491372032354079,15.584805001767407,27.899167295441107,71.71265351695844,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-06,3.319999933242798,3.4000000953674316,3.119999885559082,3.299999952316284,853522,0.0,0.0,2.978000020980835,2.546000000834465,1.9767499933640162,10.812623541533593,16.967793401601707,28.79726871791734,72.5318036792092,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-07,3.2799999713897705,3.5799999237060547,3.2799999713897705,3.5799999237060547,654320,0.0,0.0,3.060000014305115,2.591749998927116,1.9953333258628845,16.993461012091686,18.06694378592982,29.890578447904716,77.45367418671296,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-10,3.5399999618530273,3.5999999046325684,3.4000000953674316,3.4200000762939453,440405,0.0,0.0,3.116000032424927,2.632750001549721,2.012583326299985,9.756098867317412,18.355333039246016,30.814459562768786,69.76129252130117,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-11,3.4600000381469727,3.5,3.2799999713897705,3.319999933242798,293688,0.0,0.0,3.1500000238418577,2.6712500005960464,2.028916658957799,5.396822479817059,17.922321876985905,31.658931814784196,65.39013205025486,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-12,3.4800000190734863,3.4800000190734863,3.299999952316284,3.3399999141693115,402872,0.0,0.0,3.196000003814697,2.7089999973773957,2.0454999913771945,4.505629229747755,17.977113580980806,32.43705738436498,65.85099723477,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-13,3.3399999141693115,3.4200000762939453,3.2799999713897705,3.359999895095825,217740,0.0,0.0,3.243999981880188,2.7494999945163725,2.0621666570504504,3.5758296505416434,17.985087774142595,33.33063965106612,66.33378136049205,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-14,3.359999895095825,3.359999895095825,3.180000066757202,3.319999933242798,244708,0.0,0.0,3.283999967575073,2.7832499921321867,2.0790833234786987,1.0962230823134689,17.991555801973533,33.8690932057155,64.37359484456627,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-17,3.319999933242798,3.319999933242798,3.0999999046325684,3.140000104904175,448830,0.0,0.0,3.299999976158142,2.8112499952316283,2.0944166580835977,-4.848480982119248,17.38550401976057,34.22591843802164,56.309729279481616,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-18,3.140000104904175,3.200000047683716,3.0399999618530273,3.180000066757202,251549,0.0,0.0,3.321999979019165,2.84099999666214,2.11033332546552,-4.274530799482099,16.9306576178158,34.62328260562542,57.58136970913731,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-19,3.0999999046325684,3.3399999141693115,3.059999942779541,3.2799999713897705,416247,0.0,0.0,3.3239999771118165,2.8529999971389772,2.1270833253860473,-1.3237065591160762,16.50893727462894,34.12732651745941,60.663822529536986,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-20,3.240000009536743,3.380000114440918,3.240000009536743,3.380000114440918,356120,0.0,0.0,3.33199999332428,2.8769999980926513,2.1443333268165587,1.4405798683315478,15.815085002894591,34.167573768197556,63.5187508971554,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-21,3.299999952316284,3.4200000762939453,3.2799999713897705,3.319999933242798,81044,0.0,0.0,3.305999994277954,2.89549999833107,2.1614999930063883,0.4234706288286429,14.17717134116703,33.957899962968554,60.6733863240103,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-24,3.359999895095825,3.4000000953674316,3.240000009536743,3.299999952316284,158579,0.0,0.0,3.293999981880188,2.9114999949932097,2.1784166594346366,0.1821484659714928,13.137557532019525,33.65211757739816,59.71317279358511,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-25,3.299999952316284,3.359999895095825,3.180000066757202,3.2799999713897705,161896,0.0,0.0,3.289999985694885,2.918499994277954,2.195083326101303,-0.3039518039086721,12.729141413236203,32.956228111008166,58.712516422633165,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-26,3.2799999713897705,3.440000057220459,3.259999990463257,3.4000000953674316,109192,0.0,0.0,3.2960000038146973,2.928999996185303,2.2129166603088377,3.155342579865522,12.529873953819434,32.3592545855987,62.746370676888425,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-27,3.359999895095825,3.740000009536743,3.259999990463257,3.740000009536743,504405,0.0,0.0,3.334000015258789,2.9514999985694885,2.233083326617877,12.177564259742212,12.959512684217781,32.17151206980224,71.30174589779814,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-02-28,3.740000009536743,3.8399999141693115,3.3399999141693115,3.5399999618530273,728346,0.0,0.0,3.356000018119812,2.9764999985694884,2.249666660030683,5.48271581465308,12.74987467605282,32.30849047337939,62.24611525707765,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-03,3.5199999809265137,3.5999999046325684,3.4000000953674316,3.5399999618530273,216080,0.0,0.0,3.3960000038146974,3.000999999046326,2.2661666601896284,4.24028144512886,13.162279403328784,32.426270837256425,62.24611525707765,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-04,3.4800000190734863,3.5199999809265137,3.200000047683716,3.4800000190734863,428847,0.0,0.0,3.4259999990463257,3.025,2.2819999933242796,1.5761827216051456,13.256198315581017,32.55915902056436,59.61195609325301,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-05,3.4800000190734863,3.5799999237060547,3.4600000381469727,3.5399999618530273,226152,0.0,0.0,3.4519999980926515,3.0485000014305115,2.2986666599909467,2.54924576503473,13.236017597926757,32.62036007615467,61.37236114427063,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-06,3.5999999046325684,3.5999999046325684,3.4000000953674316,3.4800000190734863,189840,0.0,0.0,3.4619999885559083,3.064500004053116,2.314999993642171,0.5199315591299676,12.971120377779668,32.37581047383773,58.62069686224765,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-07,3.4800000190734863,3.5399999618530273,3.2799999713897705,3.4200000762939453,255694,0.0,0.0,3.472000002861023,3.0800000071525573,2.331166660785675,-1.4976937362968974,12.727272558381175,32.12268599082067,55.920601326834685,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-10,3.4000000953674316,3.4200000762939453,3.2799999713897705,3.3399999141693115,103619,0.0,0.0,3.4759999990463255,3.098500007390976,2.346749993165334,-3.91254559592425,12.183314208645598,32.03366427676727,52.45154648477727,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-11,3.2799999713897705,3.3399999141693115,3.0199999809265137,3.180000066757202,359755,0.0,0.0,3.4660000085830687,3.1175000071525574,2.3607499937216443,-8.25158514476709,11.17882921029476,32.05549149395196,46.26930840802775,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-12,3.119999885559082,3.4800000190734863,3.119999885559082,3.3399999141693115,338010,0.0,0.0,3.459999990463257,3.1410000026226044,2.375249992807706,-3.468210307072248,10.15600087788287,32.23871222539107,52.32127775466182,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-13,3.4000000953674316,3.5,3.3399999141693115,3.4600000381469727,233598,0.0,0.0,3.43199999332428,3.168500006198883,2.3901666601498923,0.8158521234602768,8.31623754489137,32.56397802821749,56.29713688665485,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-14,3.4600000381469727,3.4600000381469727,3.119999885559082,3.319999933242798,434689,0.0,0.0,3.4099999904632567,3.191500002145767,2.40391665995121,-2.6392978730839283,6.846310141644485,32.762506093307834,50.95823313501207,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-17,3.2200000286102295,3.2799999713897705,3.140000104904175,3.240000009536743,152881,0.0,0.0,3.3799999952316284,3.212000000476837,2.416166660189629,-4.142011416934667,5.230385888226993,32.93784958628427,48.14832047652429,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-18,3.240000009536743,3.299999952316284,3.0,3.1600000858306885,464069,0.0,0.0,3.348000001907349,3.2285000026226043,2.4278333276510238,-5.615290202197047,3.701409298053932,32.978650793390386,45.449392909323755,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-19,3.1600000858306885,3.200000047683716,3.0,3.0199999809265137,273795,0.0,0.0,3.2960000038146973,3.242500001192093,2.4385833273331325,-8.373787092498452,1.6499615297744143,32.966545159567474,41.1068170972383,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-20,3.059999942779541,3.1600000858306885,3.0,3.059999942779541,143164,0.0,0.0,3.2539999961853026,3.2564999997615813,2.4501666605472563,-5.961894702925316,-0.07676964767271022,32.90932621841433,42.7887800681887,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-21,3.059999942779541,3.0799999237060547,2.9000000953674316,2.9600000381469727,186801,0.0,0.0,3.2079999923706053,3.2615000009536743,2.46166666050752,-7.730671908149504,-1.6403497951073258,32.49153726935772,39.73361829595175,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-24,2.9200000762939453,2.9800000190734863,2.700000047683716,2.799999952316284,549060,0.0,0.0,3.153999996185303,3.260000002384186,2.4710833271344503,-11.22384414385461,-3.251533930103081,31.925943839562443,35.38073993608229,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-25,2.799999952316284,2.880000114440918,2.700000047683716,2.859999895095825,209076,0.0,0.0,3.121999979019165,3.2569999992847443,2.480333326260249,-8.392059118643944,-4.144919259908689,31.312995910736053,38.11849497706799,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-26,2.859999895095825,3.240000009536743,2.859999895095825,3.0399999618530273,713786,0.0,0.0,3.0919999837875367,3.260999995470047,2.4909166594346366,-1.6817600972562776,-5.182459733740359,30.91566043041344,45.56899579375194,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-27,3.0,3.0799999237060547,2.940000057220459,3.0,140772,0.0,0.0,3.0459999799728394,3.263999992609024,2.5009999930858613,-1.5101766341196632,-6.678921970889156,30.507796946521953,44.29276566782134,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-28,2.940000057220459,3.140000104904175,2.859999895095825,2.880000114440918,133121,0.0,0.0,3.0019999980926513,3.2629999935626985,2.5093333274126053,-4.063953488649137,-7.998774011184569,30.034537776103477,40.61757819672066,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-03-31,2.859999895095825,3.180000066757202,2.700000047683716,2.799999952316284,242456,0.0,0.0,2.9579999923706053,3.2584999918937685,2.515499994158745,-5.3414482914753645,-9.222034686841267,29.536871375883432,38.3339520222966,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-01,2.880000114440918,2.880000114440918,2.700000047683716,2.880000114440918,209222,0.0,0.0,2.9299999952316282,3.2564999938011168,2.5213333278894425,-1.7064805758389627,-10.02610161802533,29.157853020848595,41.854511560753835,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-02,2.880000114440918,2.880000114440918,2.6700000762939453,2.7699999809265137,351673,0.0,0.0,2.9049999952316283,3.2442499935626983,2.5269166618585586,-4.64716056890563,-10.45696228725333,28.387692500176787,38.59201501505193,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-03,2.7899999618530273,2.799999952316284,2.690000057220459,2.7899999618530273,165319,0.0,0.0,2.877999997138977,3.231499993801117,2.5326666623353957,-3.0576801728085727,-10.939192243238356,27.592787549125013,39.51517142401965,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-04,2.9600000381469727,2.9600000381469727,2.7799999713897705,2.8299999237060547,307252,0.0,0.0,2.8649999856948853,3.212749993801117,2.538916662335396,-1.2216426584149402,-10.824060657604935,26.540190998073278,41.412193393910954,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-07,2.7799999713897705,3.200000047683716,2.119999885559082,3.1549999713897705,536567,0.0,0.0,2.9004999876022337,3.2061249911785126,2.547374994556109,8.774348728679884,-9.532535519269844,25.859953796759065,54.0282920494457,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-08,1.3279999494552612,1.409999966621399,1.0800000429153442,1.2899999618530273,7997766,0.0,0.0,2.743499994277954,3.155374991893768,2.541124994556109,-52.97977165870069,-13.05312359621061,24.172364549306955,23.180602121820584,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-09,1.3420000076293945,1.3819999694824219,1.149999976158142,1.2259999513626099,884063,0.0,0.0,2.5620999932289124,3.102524992823601,2.535508327682813,-52.14862985040911,-17.418876587448505,22.363036987497548,22.70159316451219,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-10,1.2999999523162842,1.2999999523162842,1.149999976158142,1.1799999475479126,988437,0.0,0.0,2.3800999879837037,3.048024994134903,2.529258327682813,-50.42225311939323,-21.913370377094672,20.510624034491556,22.344200003284513,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-11,1.2000000476837158,1.2059999704360962,1.0199999809265137,1.0700000524520874,826266,0.0,0.0,2.1990999817848205,2.9917749971151353,2.5224249949057898,-51.34372873835139,-26.495141382445663,18.607094488725334,21.473609280477987,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-14,1.0820000171661377,1.0820000171661377,0.8420000076293945,0.9390000104904175,1214792,0.0,0.0,2.012999987602234,2.9367499947547913,2.5130833288033805,-53.35320336445215,-31.454839833231606,16.858440828269,20.451632447280915,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-15,0.9390000104904175,0.9399999976158142,0.6899999976158142,0.8090000152587891,2992604,0.0,0.0,1.805899977684021,2.877474993467331,2.5036583284537,-55.20239076051752,-37.24011566446567,14.930817866210452,19.461769834156044,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-16,0.8199999928474426,0.9950000047683716,0.7599999904632568,0.8830000162124634,726551,0.0,0.0,1.6171999812126159,2.8175499945878983,2.494599995017052,-45.39945421280747,-42.602616304270704,12.945963289342464,21.782496356982463,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-17,0.9240000247955322,0.9940000176429749,0.8820000290870667,0.9639999866485596,874907,0.0,0.0,1.4345999836921692,2.7571499913930895,2.486466661095619,-32.80356910589434,-47.968010874616326,10.886264213098206,24.352045291991047,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-22,0.9900000095367432,1.0479999780654907,0.8999999761581421,0.9399999976158142,495061,0.0,0.0,1.2455999910831452,2.6976499930024147,2.4782999947667124,-24.53436060172,-53.826478812515454,8.850825109909675,24.09942370137327,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-23,0.9300000071525574,1.0959999561309814,0.8999999761581421,0.9990000128746033,434874,0.0,0.0,1.0299999952316283,2.6401249945163725,2.471291661262512,-3.009707038887289,-60.9866958052754,6.831785009447577,26.128224121633323,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-24,1.1579999923706055,1.444000005722046,0.996999979019165,1.1460000276565552,781491,0.0,0.0,1.0156000018119813,2.5867749959230424,2.46625832815965,12.839703191406151,-60.738757587627624,4.886619799205031,31.071799187608107,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-25,1.149999976158142,1.2000000476837158,1.0499999523162842,1.1200000047683716,445350,0.0,0.0,1.0050000071525573,2.529774993658066,2.460758328437805,11.442785750981338,-60.27314643903081,2.8046909126616817,30.680716024005363,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-28,1.1299999952316284,1.1540000438690186,1.065999984741211,1.100000023841858,204592,0.0,0.0,0.9970000147819519,2.4637749940156937,2.4550083289543787,10.330993734481796,-59.53364178126726,0.3570930883582298,30.36412108547448,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-29,1.1579999923706055,1.1579999923706055,1.0640000104904175,1.1399999856948853,117069,0.0,0.0,1.0040000081062317,2.40377499461174,2.450091662009557,13.54581439149387,-58.232363247110044,-1.8904054944551854,31.878168484162245,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-04-30,1.1579999923706055,1.184000015258789,1.0499999523162842,1.059999942779541,264667,0.0,0.0,1.016100001335144,2.341774994134903,2.44434166153272,4.320435133029523,-56.60983638991708,-4.196085555957129,30.452104387577805,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-02,1.062000036239624,1.1799999475479126,1.062000036239624,1.1360000371932983,233848,0.0,0.0,1.048800003528595,2.283174994587898,2.4394749949375787,8.314267102529234,-54.06396767594688,-6.407116312896662,33.49581430692173,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-05,1.194000005722046,1.2000000476837158,1.1399999856948853,1.1859999895095825,182376,0.0,0.0,1.079100000858307,2.224324995279312,2.43502499461174,9.906402424821449,-51.48640584678578,-8.652888565771113,35.49589162277093,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-06,1.149999976158142,1.246000051498413,1.0499999523162842,1.215999960899353,561860,0.0,0.0,1.1042999982833863,2.167724993824959,2.430574994285901,10.115001610939256,-49.05719122909383,-10.81431352988008,36.72548790928282,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-07,1.190000057220459,1.3580000400543213,1.031999945640564,1.1200000047683716,1428429,0.0,0.0,1.122299998998642,2.1102249920368195,2.4249083280563353,-0.20493577762831033,-46.816097656232294,-12.977122985583028,34.46164617011944,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-08,1.1380000114440918,1.1740000247955322,1.0,1.0219999551773071,513323,0.0,0.0,1.1245999932289124,2.0522749930620194,2.418924994270007,-9.123247258522879,-45.20227566818444,-15.157559745610738,32.27449930563989,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-09,1.149999976158142,1.149999976158142,0.9919999837875366,1.065999984741211,294328,0.0,0.0,1.1165999889373779,1.9994249910116195,2.4129749943812686,-4.531614248386379,-44.153944561209656,-17.138594653182096,34.29090884745216,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-12,1.1160000562667847,1.1380000114440918,1.0520000457763672,1.0779999494552612,106303,0.0,0.0,1.112399983406067,1.9428749918937682,2.4069583276907602,-3.092415899313119,-42.74464450634659,-19.280904470092523,34.860525209933186,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-13,1.055999994277954,1.0800000429153442,1.031999945640564,1.0679999589920044,155334,0.0,0.0,1.1091999769210816,1.8830749899148942,2.400941661000252,-3.7143904423294605,-41.09634598401139,-21.569315052395325,34.591415339037965,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-14,1.0479999780654907,1.0980000495910645,1.0460000038146973,1.0460000038146973,195777,0.0,0.0,1.0997999787330628,1.8262249916791915,2.394658328096072,-4.89179632284968,-39.77741057404925,-23.73755494667276,33.970117778880365,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-15,1.0479999780654907,1.0839999914169312,1.0,1.0499999523162842,452032,0.0,0.0,1.0987999796867371,1.7714749902486802,2.388574994603793,-4.441211164234426,-37.972594265500334,-25.835487926870588,34.20151837605137,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-16,1.059999942779541,1.059999942779541,1.0,1.034000039100647,309499,0.0,0.0,1.088599979877472,1.718324989080429,2.382608328262965,-5.015611040427402,-36.647608176841906,-27.88050941074441,33.69287899107643,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-19,1.031999945640564,1.0820000171661377,1.0,1.059999942779541,408361,0.0,0.0,1.0759999752044678,1.6693249881267547,2.377108327547709,-1.486991895319174,-35.54281024619963,-29.774972020359016,35.374798862407005,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-20,1.0399999618530273,1.187999963760376,1.0240000486373901,1.0399999618530273,435376,0.0,0.0,1.0583999752998352,1.618824988603592,2.371358327070872,-1.738474478100333,-34.619246505898246,-31.734273554381705,34.646767025392776,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-21,1.0499999523162842,1.0579999685287476,0.949999988079071,1.0019999742507935,760737,0.0,0.0,1.0465999722480774,1.5698749870061874,2.3650416602691013,-4.26141784635098,-33.33227289365352,-33.621677225442085,33.24671649879723,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-22,1.0700000524520874,1.090000033378601,0.9580000042915344,1.0399999618530273,385301,0.0,0.0,1.0483999729156495,1.525874987244606,2.359291659792264,-0.8012219839400883,-31.29188290786333,-35.324868338704704,36.03051951209885,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-23,1.0240000486373901,1.0379999876022339,0.996999979019165,1.0299999713897705,149070,0.0,0.0,1.0447999715805054,1.4801249891519546,2.35387499332428,-1.4165391073227567,-29.411368685888544,-37.119643424155015,35.60966252685466,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-26,0.9990000128746033,1.0800000429153442,0.9990000128746033,1.0260000228881836,591704,0.0,0.0,1.0395999789237975,1.4297749906778336,2.348341659704844,-1.3081912573423398,-27.289259799477982,-39.115546293313315,35.43138702523751,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-27,1.0240000486373901,1.0240000486373901,0.9700000286102295,1.0180000066757202,363977,0.0,0.0,1.034599983692169,1.3802249908447266,2.342241659760475,-1.6044826288522325,-25.041207733894733,-41.072477082237846,35.05340153617908,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-28,1.0219999551773071,1.059999942779541,0.9959999918937683,1.0,471720,0.0,0.0,1.0299999833106994,1.3332249879837037,2.3358249932527544,-2.9126197860966303,-22.743723482979803,-42.92273642782114,34.17011839843637,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-05-30,1.0219999551773071,1.149999976158142,1.0219999551773071,1.0800000429153442,595967,0.0,0.0,1.0329999923706055,1.2902249902486802,2.3302416602770486,4.549859718476816,-19.936445179882675,-44.63127956886318,41.25515024193541,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-02,1.0880000591278076,1.100000023841858,1.0520000457763672,1.090000033378601,308048,0.0,0.0,1.0385999917984008,1.245474988222122,2.3243249942859014,4.948973809560493,-16.6101285357026,-46.415626416960365,42.09409932328824,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-03,1.149999976158142,1.149999976158142,1.0820000171661377,1.100000023841858,568470,0.0,0.0,1.0425999999046325,1.2037249892950057,2.318408328294754,5.505469397897167,-13.38553164745217,-48.079681451956525,42.97119060390212,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-04,1.1119999885559082,1.149999976158142,1.055999994277954,1.0779999494552612,437347,0.0,0.0,1.046399998664856,1.1609249889850617,2.312808327873548,3.0198729769423625,-9.86497761757451,-49.8045309248586,41.48252748525094,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-05,1.1100000143051147,1.1100000143051147,1.031999945640564,1.0779999494552612,410286,0.0,0.0,1.0539999961853028,1.1171249896287918,2.307208327452342,2.2770354228482366,-5.650665237062213,-51.581095805841684,41.48252748525094,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-09,1.090000033378601,1.090000033378601,1.0360000133514404,1.0579999685287476,179059,0.0,0.0,1.0557999968528748,1.0646999895572662,2.301191660761833,0.20837011578238135,-0.8359155435036894,-53.73266782981534,40.020757157707195,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-10,1.0959999561309814,1.0959999561309814,1.055999994277954,1.055999994277954,128802,0.0,0.0,1.058399999141693,1.0588499903678894,2.2951583276192347,-0.22675782933533664,-0.04249810929686384,-53.86592821828403,39.86945895098545,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-11,1.093999981880188,1.1160000562667847,1.0679999589920044,1.1139999628067017,208532,0.0,0.0,1.067199993133545,1.0560499906539917,2.289191660284996,4.385304532821557,1.0558214647251913,-53.86799589674736,46.219301481391405,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-12,1.1299999952316284,1.1859999895095825,1.031999945640564,1.0579999685287476,721140,0.0,0.0,1.0711999893188477,1.0529999911785126,2.283508326609929,-1.232264835858875,1.7283948996016394,-53.88674615687587,41.646415437669766,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-13,1.0199999809265137,1.059999942779541,0.9509999752044678,1.0260000228881836,1247997,0.0,0.0,1.073799991607666,1.051899990439415,2.275641659895579,-4.451477844390504,2.0819470831159976,-53.77567527535583,39.256282209150044,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-16,1.0140000581741333,1.0160000324249268,0.9729999899864197,1.0,871098,0.0,0.0,1.0657999873161317,1.0534249901771546,2.267141660054525,-6.173765068418457,1.1747392794332652,-53.535105073592106,37.37919850016664,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-17,0.9900000095367432,0.9990000128746033,0.9800000190734863,0.9959999918937683,300823,0.0,0.0,1.0563999831676483,1.058099989593029,2.2588583265741664,-5.717530503244491,-0.16066595237701217,-53.1577533152437,37.08540020725342,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-18,1.0,1.0,0.9750000238418579,0.9909999966621399,220504,0.0,0.0,1.0454999804496765,1.060799989104271,2.2437833269437153,-5.212815380837771,-1.4423085229774222,-52.72270827730948,36.697120517927054,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-19,0.9909999966621399,0.9980000257492065,0.9700000286102295,0.996999979019165,339976,0.0,0.0,1.037399983406067,1.061624988913536,2.231924992799759,-3.894351747939856,-2.281879737237618,-52.43455795609787,37.54219211916312,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-23,0.9800000190734863,0.996999979019165,0.9399999976158142,0.9679999947547913,391734,0.0,0.0,1.02639998793602,1.0623249888420105,2.2184916600584983,-5.689788958266143,-3.381733582785313,-52.11498839648563,35.1029961128752,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-24,0.9679999947547913,1.0399999618530273,0.9679999947547913,1.0379999876022339,451970,0.0,0.0,1.0243999898433684,1.0632999882102012,2.2049749925732613,1.3276061981360323,-3.6584217810733892,-51.777231406633625,44.479951061810816,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-25,1.0180000066757202,1.0640000104904175,1.0119999647140503,1.0379999876022339,369643,0.0,0.0,1.0225999891757964,1.0605999872088432,2.1886249924699466,1.5059650488408165,-3.5828774741974585,-51.54035109450542,44.479951061810816,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-26,1.0640000104904175,1.0700000524520874,1.0160000324249268,1.031999945640564,394023,0.0,0.0,1.0143999874591827,1.058399985730648,2.1723916585246723,1.7350116718223496,-4.157218335664541,-51.279504246971975,43.85010634318362,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
2025-06-27,1.031999945640564,1.031999945640564,0.9760000109672546,1.00600004196167,1005604,0.0,0.0,1.009199994802475,1.0560499861836434,2.1571083262562754,-0.3170781665958497,-4.436342218087143,-51.04325669094008,41.13208976691557,,0.421,0.0,-0.42253,-0.71476996,,1.43101,,NextCell Pharma AB,Healthcare,"NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden."
